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PM① peritoneal macrophages 
PMSF phenylmethane-sulphonyl fluoride 
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ABSTRACT 
Prehispanolone (LC-5504), a novel PAF receptor antagonist, isolated from 
Leonurus heterophvllus and its derivatives, LC-5506, LC-5507, LC-5508 and LC_ 
5509 as well as 2 classical PAF antagonists, BN52021 and BN50739 were 
compared in vitro for their ability to inhibit specific [3H]-PAF binding and PAF-
induced biological responses in thioglycollate-elicited peritoneal macrophages of 
mice and guinea pigs. Binding of pH]-PAF to peritoneal macrophages reached 
equilibrium within 1 h at 20°C. Scatchard analysis of specific binding of [
3
H]-
PAF specific binding to murine and guinea pig intact peritoneal macrophages 
revealed a dissociation constant (Kd) of 1.6 and 0.4 nM and a Bmax of 101 and 37 
fmol/lO^ cells, respectively. The order of potencies of PAF receptor antagonists to 
inhibit the binding of [^ H]-PAF to murine and guinea pig peritoneal macrophages 
was determined to be BN50739 > > LC-5507 > LC-5508 > = LC-5509 > LC-
5506 > =LC-5504 > = BN52021 in mice and BN50739 > > LC-5507 > LC-
5509 > BN52021 > = LC-5508 > = LC-5504 > = LC-5506 in guinea pigs. 
This pattern differs from that observed for the inhibitory effects of the same 
compounds on the specific binding of pH]-PAF to intact rabbit platelets. In 
addition, these PAF antagonists, with the except of BN50739, were generally 3-10 
fold more potent in platelets than in macrophages. These PAF antagonists were 
more active in guinea pig than in mice peritoneal macrophages except LC-5507 and 
LC-5508； The present study supports the possibility that the PAF receptors on 
platelets or macrophages are different. 
l 
The activation of PAF receptor on peritoneal macrophages from Balb/c mice 
and guinea pigs was accompanied by an increase in accumulation of inositol 
phosphates (IPs) including inositol trisphosphate (IP3), presumably as a result of 
hydrolysis of phosphatidylinositol bisphosphate (PIP2) by phospholipase C. The 
EC50S of PAF in stimulating [
3
H]-IPs accumulation in peritoneal macrophages 
were comparable to their Kds determined by saturation analyses of PH]-PAF 
binding. The potency of PAF antagonists in inhibiting PAF-induced [
3
H]-IPs 
accumulation also correlated with that in inhibiting the [
3
H]-PAF binding to 
peritoneal macrophages indicating the accumulation of [^ H]-IPs induced by PAF 
was likely to be receptor-mediated. 
The increase of [^ H]-IPs accumulation induced by PAF may be regulated by 
PKC activation. For instance, a PKC activator, PMA inhibited PAF-induced [
3
H]-
IPs accumulation in peritoneal macrophages. This effect was more potent in guinea 
pig than in mice. On the other hand, prolonged pretreatment of macrophages with 
10 jitM PMA enhanced PAF-induced [^ H]-IPs accumulation in Balb/c mice but not 
in guinea pigs. It may be that PKC activity of the macrophage can be down-
regulated by prolonged PMA pretreatment in mice but not in guinea pigs. 
PAF induced superoxide anion production in guinea pig thioglycollate-
elicited peritoneal macrophages but not in Balb/c mice. On the other hand, PMA 
can significantly increase superoxide production in both murine and guinea pig 
macrophages. PMA also exhibited an additive effect on PAF-induced superoxide 
production in guinea pig peritoneal macrophages only. PAF antagonists including 
BN50739 and LC-5507 can inhibit the superoxide production in guinea pig 
2 
macrophages. These data suggest that prehispanolone and its derivatives might be 
effective PAF receptor antagonists on macrophages in addition to platelets. 
3 
CHAPTER ONE. INTRODUCTION 
1.1 PLATELET-ACTIVATING FACTOR (PAF) 
During the early 1970s, Henson et aL [46,47] first described a mediator 
released from the leukocytes of antigen-sensitized rabbit, which could activate 
platelets to release vasoactive amines. This observation was subsequently 
confirmed by Sirganian & Osier [43]. During the same period, a factor was 
isolated from the renal medulla by Muirhead and co-workers [86], which could 
lower blood pressure in the Goldblatt rat model of hypertension. It was called 
antihypertensive polar renal lipid and abbreviated as APRL. In 1972, Benveniste, 
Henson, and Cochrane coined the term "platelet-activating factor" (PAF) for a 
soluble mediator released from IgE-stimulated basophils which could trigger the 
aggregation of rabbit platelets with the simultaneous release of histamine [13]. In 
1979，these biologically active substances were shown to be the same and three 
independent groups [14,16,32] proposed the chemical structure of PAF and APRL 
as l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (l-O-alkyl-2-acetyl-sn-GPC) 
(Fig. 1.1) [41]. Besides PAF, other names such as PAF-acether and alkyl glyceryl 
ether phosphocholine (AGEPC) are also used to describe this active substance. 
1-1.1 METABOLISM OF PAF 
1.1.1.1 BIOSYNTHESIS OF PAF 
PAF is produced by many different mammalian cells [23,43,45,99,118]. It 











Structure of PAF (l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) (From 
Grandel 1987). ^ ' … ^ 
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PAF production is low when cells are resting. For instance, blood cells such as 
platelets, neutrophils, basophils, eosinophils, mast cells and monocytes / 
macrophages can produce and release PAF when they are appropriately stimulated 
by ageilts such as chemotactic peptides, zymosan, thrombin and calcium 
ionophores. Other cell types which have been reported to release PAF upon 
appropriate stimulation include endothelial cells, alveolar macrophages, kupffer 
cells, large granular lymphocytes, leukemic cell lines of B- and T- cell origin and 
several lymphoid cell lines. 
There are two independent enzymatic routes for the synthesis of PAF [119], 
namely, the acetylation of l-O-alkyl-2-lyso-GPC through a remodeling pathway and 
the transfer of phosphocholine to alkylacetyl-sn-glycerol via a de novo pathway 
(Fig. 1.2) [102]. In the remodeling pathway, the membrane lipid l-O-alkyl-2-
arachidonoyl-GPC serves as the precursor for PAF. This pathway is inactive in 
resting cells but is responsible for the synthesis of PAF during cell activation. In the 
presence of an appropriate stimulus, both phospholipase A� (PLA2) and 
acetyltransferase are activated. The long-chain fatty acid at the sn-2 position of the 
1 -O-alkyl-2-acyl-GPC is hydrolysed by PLA2 and the acetyl-CoA-dependent 
acetyltransferase then acetylates the lyso intermediate to form PAF. Based on the 
inhibitory effect of anti-calmodulins, the calcium/calmodulin pathway has been 
suggested to be related to the PLA2 activation [91]. The activity of the 
acetyltransferase can be induced several fold in a rapid, transient and dose-
dependent manner after exposure to various stimuli [6,119]. When cells such as 
rabbit platelets, murine peritoneal macrophages, human polymorphonuclear (PMN) 
cells and endothelial cells as well as rabbit peritoneal PMN cells are stimulated, 
6 
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Pathways for synthesis of PAF. A, the remodeling pathway begins with the hydrolysis of a fatty 
acid from the sn-2 position of a choline phosphoglyceride that has ether-linked fatty alcohol at the 
sn-1 carbon. This reaction is catalysed by a phospholipase A?. The lyso-PAF then is acetylated in a 
reaction, catalyzed by a specific acetyltransferase. B，the de novo pathway starts with an intermediate 
in the synthesis of ether-linked membrane phospholipids. It is acetylated by a specific 
acetyltransferase, a different enzyme than in the other pathway. In subsequent steps the phosphate is 
removed from the sn-3 position and phosphocholine is added. This route is analogous to that for 
synthesis of bulk choline phosphoglycerides for membranes. The structures shown do not have the 
correct stereochemistry (From Prescott et al.t 1990). 
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radiolabeled acetate gets incorporated into PAF [119,135]. This reaction may be 
regulated by protein kinase C (PKC). While PKC activators have no direct effect 
on the basal incorporation of tritiated acetate into PAF in human PMN and murine 
peritoneal macrophages [116,135], they do greatly enhance the incorporation 
stimulated by calcium ionophores [135]. 
An alternative pathway for PAF biosynthesis is via a choline 
phosphotransferase (Fig. 1.2). It appears that the biosynthesis of PAF via this 
alternative pathway provides adequate levels of endogenous PAF in cells and tissues 
to maintain their normal physiological function [99,119]. l-O-alkyl-2-acetyl-sn-
glycerol, is the direct precursor of PAF via this pathway and it comes from 1-0-
alkyl-2-lyso-sn-glycero-3-phosphate via an acetylation-dephosphorylation sequence 
[66,119]. The acetyltransferase responsible for the transfer of the acetate group 
from acetyl-CoA to l-0-alkyl-2-lyso-sn-glycero-3-phosphate is different from the 
acetyltransferase involved in the remodeling pathway in their pH optimum and their 
sensitivities to elevated preincubation temperatures [119]. Subsequent to 
acetylation, the phosphate group is removed by a phosphohydrolase and then 
phosphocholine is added to the C3 position to form PAF. The last step is catalyzed 
by a dithiothreitol (DTT)-insensitive choline phosphotransferase [119]. It should 
be noted that the choline phosphotransferase which utilizes long-chain diacyl 
glycerols as substrates is inhibited by 5-10 mM dithiothreitol, whereas the choline 
phosphotransferase which is highly specific for short chain diacyl glycerols is 
insensitive to DDT. Moreover, the optimal pH for the DTT-insensitive choline 
phosphotransferase is 8.0 while that for the DTT-sensitive phosphotranferase is 8.5. 
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1.1.1.2 DEGRADATION OF PAF 
Degradation of PAF to its inactive products is initiated by a PAF 
acetylhydrolase [23,66,91,102,119,130] which converts PAF into lyso-PAF by 
removing the acetyl group from the sn-2 position (Fig. 1.3) [66]. This is a cytosolic 
enzyme present in a variety of cells and tissues. It acts specially on GPCs with a 
short-chain (2 to 6 carbons) fatty acid at the sn-2 position. After deacetylation by 
the cytosolic acetylhydrolase, lyso-PAF can be acylated by a membrane-bound 
transacylase, forming preferentially 1 -O-alkyl-2-arachidonoyl-GPC [82,124]. The 
l-O-alkyl-2-acyl-GPC thus formed can act as a precursor and be converted to PAF 
when the cell is stimulated again (Fig. 1.3). It has been reported that the calcium 
ionophore A23187 can stimulate simultaneously the activity of acetylhydrolase in 
PAF degradation and acetyltransferase in the remodelling pathway of PAF synthesis 
in alveolar macrophages [124]. This suggests that intracellular calcium level may 
be important in the regulation of accumulation of PAF in cells. In addition, 
phorbol- 12-myristate-13-acetate (PMA) can potentiate this A23187 effect on the 
acetylhydrolase which suggests that PKC may also be involved in the regulation of 
this enzyme. Macrophages can synthesize and release PAF acetylhydrolase into the 
plasma [102]. PAF can be rapidly deacetylated in the plasma with a half-life of 7 
min [91]. This plasma enzyme is located together with both the light and heavy 
density lipoproteins [91,102] and is much more active in the low density than the 
high density lipoprotein fraction [102]. Although the plasma form has similar 
biological properties as the intracellular form [23,66,91,102,119], it differs from 
the cytosolic enzyme in having a higher molecular weight and is resistant to serine 
hydrolase inhibitors such as PMSF (Fig. 1.4) [23]. 
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The PAF actiyation-inactivation cycle. The Roman numerals refer to the enzyme 
that catalyze the following reaction steps: I — phospholipase A� (EC 3.1.1.4), n — 
- acetyl-CoA: 1 -alkyl - 2 -lyso - sn - glycero- 3- phosphocholine acetyltransferase 
(EC 2.3.1.67), HI ---- l-alkyl-2-acetyl-5n-glycero-3-phosphocholine acetylhydrolase 
(EC 3.1.1.48), and IV --- acyl-CoA: l-alkyl-2-lyso-jn-glycero-3-phosphocholine 
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Fig. 1.4 
A schematic diagram showing the location of different enzymes involved in the 
inactivation of PAF in both the extracellular and intracellular compartments. PAF 
interacts with its receptor to induce a biological response, initially phosphoinositide 
breakdown. After crossing the membrane, PAF is deacetylated by cytosolic 
acetylhydrolase. PAF is stored in the membrane in the form of its precursor, 
alkylacyl-GPC (From Braquet et al，1987). 
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1.1.2 SYSTEMIC EFFECTS OF PAF 
PAF is one of the most potent lipid mediator involved in many biological 
responses. Its activities extend far beyond the activation of platelets implied by its 
name. The production of PAF is normally under strict control. However, when the 
balance is upset, it can give rise to devastating pathological changes (Fig.l.5)[118]. 
PAF plays an important role in inflammatory reactions. It mounts a non-
specific immune response during tissue injury by inducing chemotaxis, secretion 
and oxygen radical generation from human PMN cells, monocytes and eosinophils. 
The PMN cells, macrophages and eosinophils can phagocyte invading bacteria and 
their secretory products such as reactive free radicals are extremely toxic to any 
invading organism. The release of cytokines such as IL-1 and TNF from these 
inflammatory cells can further amplify the inflammatory response. Platelets can 
also play a role in the inflammatory reactions as they release histamine and other 
active substances when activated by PAF [26,90]. PAF also induces vasodilation 
and increases vascular permeability [23,26,41，43,66,119] which can lead to edema 
commonly observed in inflammatory reactions. 
PAF also plays an important role in other immune responses such as asthma 
and graft rejection. The role of platelets in asthma has been studied for a long time 
[90,95]. Secretions from platelets, including histamine, arachidonic acid (AA) 
metabolites and PAF, induced by allergen exposure are known to play an important 
role in asthma [23,66,90,106,109,119]. PAF can also induce bronchoconstriction 
directly [23,33,66,90,106,119]. PAF antagonists on the other hand can attenuate 
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Fig. 1.5 
Diseases in which PAF has been proposed as a contributing factor (From Snyder et 
al.，1990). 〜 
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models and in clinical trials [105,117]. Graft transplantation rejection is a cell-
mediated immune response. PAF antagonists, including ginkgolide derivatives [23] 
and SRI 63-441 [76], alone or in combination with cyclosporine can significantly 
prolong the graft survival time. This is presumably the result of their inhibition of 
lymphocyte proliferation [134] which requires interleukin-1 (IL-1) and antigen 
presentation from macrophages [20,23]. 
As mentioned in section 1.1, PAF is a potent hypotensive agent and can be 
used in the treatment of hypertension. Indeed, PAF has been reported to increase 
the pulmonary vascular resistance and induce right ventricular failure and systemic 
hypotension [12,23,38,41,66,119]* PAF antagonists have also been reported to 
protect animals from endotoxin-induced hypotension, which further supports the 
role of PAF in septic shock [125,129], 
In ischemic animal models including myocardiac, renal and cerebral 
ischemia, PAF plays an important role in the post-ischemic phase 
[22,48,101,120,121]. Antagonists of PAF have been reported to provide protection 
against the damage induced by ischemia in these organs. A hypothesis proposed by 
Braquet et al (1989) on the homeostatic control of PAF, IL-1 and tumour necrosis 
factor (TNF) auto-generated feedback cycles may explain why PAF antagonists are 
effective in preventing ischemic injury and many other disorders such as shock, 
asthma and graft rejection (Fig. 1.6) [22]. PAF induces the synthesis and release of 
IL-1 and TNF from macrophages [17,22,83,100,133]. TNF and IL-1, in turn, 
stimulates PAF production by the endothelial cells [21,22]. This positive feedback 
cycle can be down regulated by endogenous inhibitors such as PAF, IL-1 and TNF 
14 
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Fig. 1.6 
Scheme showing the homeostatic control of PAF, IL-1 and TNF auto-generated 
feedback cycles by endogenous regulators. A breakdown in the regulatory process 
may lead to microvascular injury such as that observed in ischemia, shock and graft 
rejection (From Braquet et al” 1989). 
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or by external agents such as PAF antagonists. Indeed, PAF antagonists have been 
reported to decrease TNF synthesis and release in LPS-treated mice [37]. 
It has also been reported that PAF may be involved in gastric and duodenal 
ulcer p，23，43], glomerular nepritis, nephrotic syndrome, glycerol-induced acute 
renal failure [23,75] and regulation of ovulation [2]. PAF is found in amniotic fluid 
from women at term and in labour [118]. Since PAF can initiate uterine 
contraction in animals and it has been suggested that PAF may be involved in the 
induction of labour [23]. 
1.1.3 STRUCTURE-ACTIVITY RELATIONSHIP OF PAF 
At the 1 position, compounds containing a 16-carbon straight-chain alkyl 
ether are the most active. Analogues with longer or shorter alkyl ethers or no alkyl 
ether have lower activity in stimulating various cell types (Table 1.1) [23,66,119]. 
It has also been shown that 1-O-alkyl derivative is about 300-folds more active than 
the fatty acyl derivative [43]. At the 2 position，an acetyl substituent gives the 
optimal biological activity [43,119], and activity decreases.as the acyl substituent 
gets bigger (Table 1.2) [43]. Absence of substituent or substitution with branched-
alkyl residues results in a marked decrease in activity [119]. At the 3 position, 
analogues with no phosphocholine are almost inactive. The biological activity of 
PAF is stereoselective [66，119]. Naturally occurring PAF is a R-(=L) stereoisomer 
and the S-(=D) stereoisomer is inactive in general except 1 -(S)-methyl-PAF which 
possesses stronger antihypertensive effect than the R-stereoisomer [66,119]. 
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Table 1.1 Biological Activities of Various AGEPC Homologs and Analogs 
(From Winslow et aL, 1987). 
Molecular species Relative PAF activity (5^ )! 
l-0-alkyl: 
Cp:0-AGEPC 8 









C^ O-AGPC 0.3 
C18:0-AGPC 0.02 
1 PAF activity is expressed as a percentage relative to the platelet stimulating activity of C,6:0-AGEPC; 
C!6:0-AGEPC induced secretion of 50 per cent of the serotonin from washed rabbit platelets at 0.14 
nM (final concentration) in 60 sec at 37 °C. 





Table 1^2 Biological activity of synthetic l-0-alkyl-2-acyl-5n-glycero-3-
phosphocholines. Activity based on ability of derivatives to cause 50 % secretion of 
serotonin from washed rabbit platelets. (From Hanahan et al., 1986). 
Substituent at position Biological activity 
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„
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1.2 PAF RECEPTORS 
Many of the cells or tissues which produce PAF are often the targets of PAF 
themselves. There are ample evidence supporting the existence of specific receptors 
on a variety of cells and tissues which respond to PAF. Up to now, radioligand 
binding studies have demonstrated the existence of PAF receptors [91] on platelets, 
PMN cells, macrophages, eosinophils [65], Kupffer cells [27], human 
lymphoblastoid B cells [112] and membrane preparations of the lung and liver [91]. 
1.2.1 PAF RECEPTOR ON PLATELETS 
Specific binding of [
3
H]-PAF has been reported on intact canine,platelets 
[57], human intact platelets [63] and platelet membranes [126] as well as rabbit 
platelet membranes [54,56,114]. Most studies reported only a single class of 
binding sites on platelets with a kd of 0.07 nM in human platelet membrane [126], 
0.2 nM in human intact platelets [126] and 1 nM in rabbit platelet membranes [57]. 
Sodium ions markedly inhibit the specific binding of [
3
H]-PAF to rabbit platelet 
membranes while divalent cations, including Mg2+，Ca2+ and enhance 
the specific binding [54]. Increasing incubation temperature on the other hand 
decreases the PAF receptor affinity for PAF. PAF antagonists are able to inhibit the 
binding of [^ H]-PAF to platelets as well as the biological responses induced by 
PAF such as platelet aggregation, secretion of active substances, including ATP, 
histamine, ADP and AA metabolites [5,57,63,114,126]. It should be noted that 
several PAF antagonists exhibited different potency in platelets from men and 
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rabbits [53]. Whether there are different subtypes of PAF receptors on platelets in 
different species remain to be explored. 
1.2.2 PAF RECEPTOR ON LEUKOCYTES 
In 1988, Hwang et al. [52] identified a second receptor subtype of PAF on 
human PMN which differs from those on human platelets in pharmacology. Similar 
results have been reported in rabbit platelets and PMN cells by Panlson et al 
(1990) [97]. Moreover, pertussis toxin and cholera toxin inhibit the GTP hydrolysis 
induced by PAF in human PMN but not in human platelets [52]. 
1.2.3 PAF RECEPTOR ON MACROPHAGES 
Stewart and co-workers (1988) compared the characteristics of PAF 
receptors on platelets, PMN and macrophages [122]. They found that WEB 2086 is 
10 fold less potent as an inhibitor against PAF's effect in resident peritoneal 
macrophages than against PAF-induced aggregation of platelets and PMN. 
Moreover, kadsurenone has been reported to inhibit the chemiluminescence 
production from PAF-activated peritoneal macrophages and PAF-induced 
aggregation of peripheral PMN with pA2 values of 8.1 and 6.2 respectively [69]. 
These data suggest that PAF receptors on macrophages may be different from those 
on the platelets and PMN. 
1.2.4 ANTAGONISTS OF PAF 
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Depending on their site of action, PAF antagonists can be divided into two 
groups: the specific antagonists which act directly at the PAF receptor and the non-
specific inhibitors which inhibit PAF's biological action at sites other than the 
receptor 123,110,119]. The discovery and development of specific antagonists for 
PAF are useful not only in the studies of the biological and pathological response to 
PAF, they also facilitate the characterization of PAF receptors. 
1.2.4.1 NONSPECIFIC INHIBITORS GF PAF 
Drugs which interfere with the second messenger system of PAF can 
interfere with the biological response to PAF [18,19,23,29,71,94]. These 
compounds include the calcium-related drugs such as calcium channel blockers, 
calmodulin inhibitors and calcium chelators; the cyclic nucleotide modulators such 
as li2-agonists, prostaglandin I2, prostaglandin E^  and phosphodiesterase 
inhibitors; and inhibitors for phospholipase C. 
Other compounds, such as glucocorticoid, cromoglycate, thyrotropin-
releasing hormone, MK 771，atropine, C reactive protein and several antidepressant 
agents have also been reported to inhibit the effect of PAF without a direct 
interaction with the PAF receptor. 
1.2.4.2 SPECIFIC ANTAGONISTS OF PAF 
According to their structures and sources, specific antagonists of PAF 
receptors can be divided into three groups [19,23]. 
A. Structurally-related analogues : 
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In this group, the compounds were derived on the basis of the structural 
framework of PAF (Fig. 1.7) [110]. Modification of the structure of PAF resulted 
in a series of compounds such as CV-3988, 0no-6240 and the SRI compounds 
which can compete with PAF for binding to PAF receptors and inhibit the 
biological response of PAF [23,29,110,127]. They have also been reported to 
inhibit a wide range of pathological events induced by PAF [Table 1.3]. 
B. Natural products 
Several naturally occurring PAF antagonists have been isolated from 
medicinal herbs. For example, kadsurenone was isolated from Piper futokadsurae 
[19,110] and a series of BN compounds were isolated from Ginkgo biloba. 
[19,110]. More recently, our laboratory isolated another novel PAF receptor 
antagonist, prehispanolone, from Leonurus heterophvllus. The structure of 
prehispanolone and its derivatives are shown in Fig. 1.8 [72]. 
« 
C. Synthetic compounds 
RP-48740 and FR-49175 are synthetic compounds with no structural 
resemblance to PAF. They also exhibit specific antagonistic activity at the PAF 
receptor [19,110]. 
More recently, triazolobenzodiazepines (TBDZ), a classical psychotropic 
agent [23,62] as well as amiloride and its analogs have been reported as selective 
antagonists of PAF as well. 
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PAF antagonists structures (From Saunders et al” 1987). 
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Table 1.3 
Summary of PAF antagonist activity (From Saunders et al.，1987). 
Clinical condition Animal model Compound rcfcrence 
Asthma/Pulmonary PAF-induced BN 52021 (124), FR-49175 (139), 
dysfunction bronchoconstriction L-652-731 (111), RP-48740 
(123, 124), ONO-6240 (85), SRI 
63-072 (102), SRI 63-119 (99), 
SRI 63-441 (80)，broiizolara 
(128) 
Antigen-induced BN 52021 (110) 
bronchoconstriction 
Endotoxin-induced pul- ONO-6240 (112) 
monary dysfunction ^ 
Septic shock PAF-induced hypoten- Kadsurenone (86), BN 52021 (87, 
sion 124), L-652-731 (131), RP-
48740 (123, 124), CV-3988 (83, 
84), ONO-6240 (85), SRI 63-
072 (61), SRI 63-441 (80) 
Endotoxin-induced Kadsurenone (86), CV-3988 (84)， 
hypotension BN 52021 (104), SRI 63-072 
(61) 
Immune complex- BN 52021 (87), L-652-731 (131)， 
induced hypotension SRI 63-072 (61) 
Inflammation PAF-induced vascular Kadsurenone (28, 105’ 129), BN 
permeability 52021 (87, 104), L-652,731 
(100, 129，130), CV-3988 (29, 
98’ 103), RP-48740 (123), 
ONO-6240 (85), SRI 63-072 
"(21, 46), SRI 63-119 (46, 99), 
SRI 63-441 (80) 
Carrageenin-induced Kadsurenone (129), L-652-731 
edema (129) , » 
Immune complex- BN 52021 (87), L-652-731 (100, t,, 
induced vascular per- 丨31)，SRI 63力72 (116), CV- , 
meability 3988 (103)
 k 
Ulcerogenic! Endotoxin-induced CV-3988 (114), ONO-6240 (118, ‘ 
Enterocolitis 160), SRI 63-072 (118, 160), 
SRI 63-119 (11,8, 160) 
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Fig. 1.8 
Chemical structures of prehispanolone and its related analogues (From C.M. Lee et 
aL，1991). 25 
Interaction of PAF with its specific receptor activates multiple biochemical 
pathways. In platelets, PAF induces shape change, platelets aggregation and 
degranulation. In macrophages, PAF elicits responses such as phagocytosis, 
secretion of interleukin I (IL-1), prostaglandins and thromboxanes as well as 
production of superoxide [37]. The activation of a PAF receptor coupled GTPase, 
followed by an increase in Ca2+ uptake, protein phosphorylation and turnover of 
polyphosphoinositide and arachidonic acid have been implicated as the underlying 
mechanisms for these biological responses (Fig. 1.9) [66,119]. The roles of 
adenylate cyclase, polyphosphoinositides and protein kinase C (PKC) have been 
extensively studied as possible second messenger systems of PAF. 
1.3.1 ADENYLATE CYCLASE-CYGLIC ADENOSINE MONO-
PHOSPHATE SYSTEM 
G protein functions as an intermediate in several transmembrane signaling 
pathways. Such pathway generally consists of receptors, G proteins and effectors 
[31]. The adenylate cyclase system is a common effector system located in the cell 
plasma membrane [111]. Several G proteins have been characterized. Gs is the 
stimulatory regulator of adenylate cyclase (AC) and Gi mediates the inhibition of 
AC. Cyclic adenosine monophosphate (cAMP) formed from adenosine 
triphosphate (ATP) by adenylate cyclase, has been implicated as an important 
mediator in many processes. When PAF binds to its receptor, a G protein 
analogous to Gi is activated [119]. The activation of G-protein by PAF can be 
monitored conveniently by measuring the PAF stimulated hydrolysis of GTP in 
human platelet and neutrophil membranes [52,91,119]. 
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Fig. 1.9 
Biological pathways mediating platelet activation by PAF (From Snyder, 1987). 
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However, the role of AC inhibition in platelet activation remains 
controversial. Some reported that PAF had no effect on the basal level of cAMP in 
rabbit platelets [66] and guinea-pig alveolar macrophages [9] but others observed a 
decrement of basal level of cAMP in human platelets in the presence of PAF [8]. 
PAF has been shown to reverse the increase of cAMP induced by PGEi in rabbit 
platelets [66] and by PGE2 and salbutamol in guinea-pig alveolar macrophages [9]. 
On the other hand, dibutyryl cAMP did not inhibit the PAF-induced platelet 
aggregation [58]. 
1.3.2 PHOSPHOLIPASE C - PHOSPHATIDYLINOSITOL SYSTEM 
PAF stimulates phospholipase C activity in platelets and other target cells 
[119]. Phospholipase C (PLC) cleaves various phospholipids at the 3-position 
leaving behind diacylglycerol (DAG) as a common product. The 
phosphatidylinositol(PI)-hydrolyzing PLC (PI-PLC) and sphingomyelin(SM)-
hydrolyzing PLC (SMase-C) are both very specific, whereas the 
phosphatidylcholine - hydrolyzing PLC (PC-PLC) can accept phosphatidylcholine 
(PC), phosphatidylserine (PS) and SM as substrates [74], PI-PLC seems to be 
independent of metals for its activity [81], whereas SMase-C is a Mg2+ -
containing enzyme and PC-PLC a -enzyme. The products produced by PI 
hydrolysis by PI-PLC, inositol trisphosphate (IP3) and DAG, are closely related to 
intracellular Ca2+ mobilization and protein kinase C (PKC) activation. 
Stimulation of rabbit platelets [108], human neutrophils [108], murine 
macrophages [50], rat kupffer cells [39] and U937 cells [30] with PAF induced an 
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enhancement of turnover of phosphatidylinositol phosphate (PIP) and 
phosphatidylinositol 4,5-bisphosphate (PIP2), a rapid formation of inositol mono-
phosphate (IP)，inositol bisphosphate (IP2), IP3 and phosphatide acid 
[70,79,89,119]. The enhanced PI metabolism induced by PAF can be antagonized 
by specific PAF antagonists, CV-3988 and SR 163-675 [41]. Since DAG 
accumulation proceeds at a slower rate than the accumulation of inositol 
phosphates, it has been suggested that other phospholipids in addition in PI may be 
responsible for the PAF-induced DAG accumulation in murine peritoneal 
macrophage [98，131]. 
1.3.3 INTRACELLULAR CALCIUM 
Ca2+ plays an important role in signal transduction in cells. 
Ca2 ./calmodulin and protein kinase C activation are believed to be two parallel 
Ca2+-dependent pathways for protein phosphorylation. Ca^
+
/calmodulin-
dependent myosin light-chain kinase phosphorylates myosin light chain and 
Ca2+/PS-dependent protein kinase C phosphorylates a 40 KDa protein in platelets. 
These are important events prior to shape change, aggregation and degranulation in 
platelets [70,73,79,89]. PAF can induce a rapid and transient increase in IP3 which 
in turn can release from intracellular stores in platelets, eosinophils and 
macrophages [28,64,104,119]. The IP3-induced Ca2+ mobilization in 
permeabilized platelets is pH dependent [115], especially at low concentrations of 
IP3. PAF also elevates cytosolic level by stimulating the influx of external 
Ca2+ through the plasma membrane [64]. The latter effect may be related to the 
opening of receptor - linked calcium channels. 
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1.3.4 THE ROLE OF PROSTAGLANDINS AND LEUKOTRIENES 
PAF-induced platelet aggregation is associated with the release of 
thromboxane B�(TXB2), an arachidonic acid (AA) metabolite. However, there is 
no dose-dependent increase in TXB2 formation with increasing concentration of 
PAF [67,68,80], an observation also confirmed in our laboratory (unpublished 
observation). It is likely that the thromboxane release was secondary to the PAF-
induced calcium mobilization and platelet aggregation. Indeed, the synthesis of 
TXB2 was inhibited if increases in intracellular Ca2+ level was prevented by using 
a Ca2+ _ EGTA buffer [7]. On the other hand, PAF can stimulate the production 
of LTB4 and LTE4 in human monocytes in a time and concentration-dependent 
manner [36]. A23187, a calcium ionophore, potentiates the effect of PAF in 
stimulating TXB2 and LTB4 synthesis in human neutrophils [128]. 
1.3.5 PROTEIN KINASE C 
Protein kinase C (PKC) is a complex family of related enzymes. Protein 
chemistry and molecular cloning techniques have identified at least seven isoforms 
within a given mammalian species : a,泠丄，卢2，7? e and f [34,59]. These 
multiple molecular forms are derived from multiple genes and alternative splicing 
of a single RNA transcript They all possess a high -degree of sequence homology. 
Many cells types express more than'one isoforms in different ratios. For example, 
7-PKC is primarily expressed in the CNS and is sparse in other tissues. a-PKC, on 
the other hand, is widely distributed in many tissues such as the liver and spleen 
[59]. The intracellular distribution of PKC isoforms is also different. 7-PKC 
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appears to be associated with cell membranes, whereas i^-PKC is present 
predominantly in the cytosol. 
In general, the presence of Ca
2+
, DAG and phosphatidylserine are required 
to activate PKC. However, there are evidence that some PKC isoforms exhibit 
different activation requirements [34,35,59,88,96]. The 7 isoform shows less 
activation by DAG but is obviously activated by free AA in the absence of Ca
2
+, 
DAG and phospholipid [113]. It has also been reported that PKC 
autophosphorylation at pH 4 to pH 6 can by-pass the Ca
24
" and lipid requirement 
[81]. 
1.3.5.1 DUAL ACTION OF PKC 
Ample evidence suggested that PKC has a dual action, namely positive feed-
forward control and negative feedback control, on various signaling processes 
(Fig. 1.10) [59]. A positive feed-forward action of this enzyme is involved in gene 
expression and growth regulation [59], PKC can activate both the Ca
2+
-transport-
ATPase and the Na+/Ca
2
+ exchange protein to remove Ca
2
+ from the cytosol 
[59]. On the other hand, PKC exerts a negative feedback control on PI metabolism 
and intracellular increase of Ca
2+
. Oleic acid, a PKC activator, inhibits the 
synthesis of PIP and PIP2 as well as protein phosphorylation induced by PAF in 
platelets [89]. PMA and OAG also inhibit PAF-induced increase in intracellular 
calcium in a dose-related manner in platelets [132]. When pretreated with 
staurosporine, a protein kinase C inhibitor, PAF-induced IP3 accumulation was 
enhanced [84]. In neutrophils, PMA inhibits PAF-induced intracellular Ca2+ 
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Fig. 1.10 , u U1 
Dual action of protein kinase C and TPA. This schema is probably 
oversimplified，but emphasizes a negative feedback action of PKC on membrane 
functions. Unlike transiently produced diacylglycerol, TPA appears to show a dual 
effect with a positive action to immediately activate PKC, and with a negative 
action to initiate the degradation of the enzyme during sustained activation. DG 
represents diacylglycerol, and IP3 indicates inositol-l,4,5-triphosphate. (From 
Kikkawa et ah, 1989). 
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mobilization, degranulation and AA release [92,136]. At high concentration, this 
PKC activator is able to reduce [
3
H]-PAF binding to neutrophils by > 75% [92]. 
1.3.5.2 DOWN REGULATION OF PKC 
Prolonged treatment (16 hr) of macrophages from C57 mice with 16 mM 
phorbol esters can result in a down regulation of total PKC activity to eventually 
undetectable levels while the same treatment had little effect on cAMP 一 dependent 
and Ca^
+
/calmodulin-dependent kinase activities [78,131]. Immunoblot analyses 
with PKC isozyme specific antibodies revealed that 20 nM phorbol ester induced a 
fast translocation of a and b PKC activities from the cytosol to the cell membrane, 
followed by their proteolytic degradation [49]. Over 90% of the cytosolic b 
isozyme was lost after 5 minutes. However, significant degradation of a isozyme 
was only observed after 10 to 30 minutes. Thus, different PKC isozymes are down-
regulated at different rates. This may explain the differences in sensitivity and rate 
of phorbol ester induced down-regulation of protein kinase C observed among 
different cell lines such as Swiss373, V79, MDBK and C^  cells [4]. 
1.4 THE FUNCTIONS OF MACROPHAGES 
Macrophages are phagocytes derived from the bone marrow stem cells. 
They are distributed in most tissues, circulate through secondary lymphoid organs 
such as the spleen and lymph nodes. They have been shown to have receptors for 
the Fc region of immunoglobulin, C35 and C55, 
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1.4.1 PHAGOCYTOSIS 
Phagocytosis is the process whereby phagocytes engulf particles and micro-
organisms [77,107]. The particle to be "ingested" first attaches to the cell 
membrane of macrophages via non-specific receptors or receptor for opsonins such 
as immunoglobulin or complement. Then the macrophage extends pseudopodia 
around the particle and engulfs it to form a phagosome which subsequently fuses 
with lysosomes. The enzymes in the lysosome will digest the phagocytosed 
materials and the digested products are finally released. 
1.4.2 ANTIGEN PRESENTATION 
One of the critical step in the development of an immune response requires 
the presentation of an antigen to T and B lymphocytes. Antigen from the periphery 
may be carried free or on the surface of antigen presenting cells (APCs). When an 
antigen is taken up by phagocytes or APCs, it can be degraded either completely or 
partially. For those partially degraded antigens, they are presented on the cell 
surface in association with class II MHC molecules so that T-helper cells and T-
cytotoxic cells can recognize them [107]. Macrophages (one of the APCs) can 
present antigens to both T and B cells. 
1.4.3 RELEASE OF CYTOKINES 
In the presence of an appropriate stimulus, macrophages can synthesize and 
release cytokines such as interferon (IFN), PAF, interleukin-1 (IL-1) and 
interleukin-6 (IL-6). IL-1 can enhance the release of interleukin-2 (IL-2) and 
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expression of JL-2 receptor on T-helper cells. IL-1 is also an inflammatory 
mediator and pyrogen that causes fever [77]. IL-6 is related to the growth and 
differentiation of B cells whereas IFN can activate lymphocytes and macrophages as 
well as enhance the induction of MHC. 
1.4.4 RESPIRATORY BURST 
Respiratory burst is a distinguishing property of phagocytes [10]. These cells 
contains a membrane bound enzyme, NADPH: 02-oxidoreductase (NADPH-
oxidase), which constitutes a transmembrane electron transport system. Electrons 
are transferred from the cytosolic NADPH to extracellular oxygen in the production 
of superoxide (O2") at the outer surface of the plasma membrane [10]. The 
production of superoxide is essential for the killing of micro-organisms, but it may 
also be a cause of tissue damage and inflammation. This response can be induced 
by phagocytosis or by the addition of chemical activators. This reaction can be 
monitored in the form of cyanide-insensitive consumption of oxygen, production of 
O2" or production of H2O2 which arises by the spontaneous dismutation of O2"： 
202" + 2H+ > O2 + H2O2 
The production of O2" is commonly measured by the dismutase-sensitive 
reduction of added cytochrome C. On the other hand, the production of H2O2 can 
be measured by the oxidation of chromogenic, fluorogenic or luminogenic H-
donors catalysed by added peroxidase. Huang et al. (1988) reported that phorbol 
ester was shown to activate respiratory burst in normal bone marrow-derived 
macrophages whereas the calcium ionophore, A23187, did not [50]. PAF can 
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induce the superoxide production in macrophages [1,44,50], PMN [60,93] and 
eosinophils [61]. Although l-oleoyl-2-acetylglycerol (OAG), a PKC activator, has a 
synergistic effect on the PAF-induced 〇2_ production in guinea-pig PMN [93], 
PKC may not be the sole signal for the initiation of respiratory burst. For example, 
the respiratory burst induced by formyl-methionyl-leucyl-phenylalanine (fMLP) is 
neither inhibited by staurosporine nor accompanied by an accumulation of DAG or 
increase in intracellular Ca
2
+. However, after the pretreatment with PAF, the 
respiratory burst response is partly sensitive to staurosporine and is accompanied by 
an accumulation of DAG as well as an increase in intracellular Ca
2+
 [61]. 
It has been suggested that the respiratory burst was mediated by two distinct 
signal transduction pathways. One is Ca
2+
-dependent and involves an activation of 
PKC. The other is Ca
2+
-independent and does not involve PLC and PKC [10]. 
As mentioned above, PAF is involved in many pathophysiological events. 
The discovery and characteristics of PAF antagonists will help to treat some of 
these disorders. While a lot of work has been done on the characterization of PAF 
receptors in platelets, relatively little information is available on the PAF receptors 
on immune cells. In the present study, I have attempted to study the biochemical 
and pharmacological properties of the PAF receptors on macrophages from mice 
and guinea pigs. Since our laboratory have recently characterized prehispanolone 
and its derivatives as novels and specific PAF antagonists in rabbit platelets, I have 
also examined their effects on macrophages for comparison. The possible existence 
of multiple subtypes of PAF receptors on different cell types will also be discussed 
in light of the present findings. 
36 
CHAPTER TWO. METHODS 
2.1 PREPARATION OF PERITONEAL MACROPHAGES 
2.1.1 PREPARATION OF REAGENTS 








 free) containing 142 mM NaCl, 4.2 mM 
NaHC03, 0.27 mM Na2HP04.2H20, 5.4 mM KC1, 0.44 mM KH2P04 and 5.5 
mM glucose was adjusted to pH 7.2 (at room temperature) and stored at 4°C. 
(2) Phosphate buffered saline (PBS) 
PBS containing 140 mM NaCl, 2.7 mM KC1, 1.5 mM KH2PO4 and 8.1 
mM Na2HP04.2H20 was adjusted to pH 7.2 and stored at 4°C. 
(3) Lysing Solution 
Lysing solution containing 17 mM Tris.HCl and 144 mM NH4CI (KOCH-
LIGHT LTD) was adjusted to pH 7.2 and stored at 4°C. 
(4) 3 % (w/v) Thioglycollate Medium 
Fifteen grams of thioglycollate medium (Difco) were dissolved in 500 ml 
double distilled water and the medium was sterilized by autoclaving at 121°C for 30 
min (Mishell & Shiigi，1979). It was stored at room temperature and prevented 
from exposure to light. 
2.1.2 PREPARATION OF PERITONEAL MACROPHAGES 
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Female Balb/c mice (6-8 weeks) and female Dunken Hartley guinea pigs 
(450 - 700 g) were anaesthetized with ether. Thioglycollate-elicited peritoneal 
exudative cells (TG-PEC) were induced by injecting 2 ml (for Balb/c mice) or 20 
ml (for guinea pigs) of 3 % thioglycollate intraperitoneally. Peritoneal lavage was 
obtained 3 - 5 days later by injecting 10 ml (for Balb/c mice) or 50 ml (for guinea 




 free) into the peritoneal cavity. Cells 
in the peritoneal lavage were pelleted by centrifugation at 110 g for 5 min at 4°C. 
They were resuspended in 50 ml of lysing solution to lyse the red blood cells. The 
cell suspension was centrifuged at 110 g for 5 min at 4°C and the cells were 
washed with cold PBS again. Further purification of PEC was achieved by 
incubation in 90 mm
2
 culture dish (Falcon) at 37°C for 2-3 h to allow the 
macrophages to adhere to the bottom of the dish. Nonadhesive cells in the 
supernatant were removed and the monolayer of adhesive cells was washed with 2 x 
10 ml of warm PBS (37°C). 
Resident peritoneal exudative cells (resident PEC) were obtained similarly 
from animals receiving no thioglycollate pretreatment. 
2.2 RADIOLIGAND BINDING ASSAY 
2.2.1 REAGENTS 
(1) Buffer A - 0.25 % (w/v) bovine serum albumin (Sigma) in 50 mM 
Tris.HCl, pH 7.4 
(2) Buffer B - 0.3 M sucrose in 50 mM Tris.HCl, pH 7.4 
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(3) Buffer C - 0.25 % (w/v) bovine serum albumin in Buffer B 
2.2.2 [
3
H]-PAF BINDING TO TG-PEC 
2.2.2.1 PREPARATION OF THIOGLYCOLLATE-ELICITED 
PERITONEAL MACROPHAGES 
Peritoneal exudative cells were harvested as described in section 2.1.2. The 
cell suspension was centrifuged at 110 g for 5 min at 4°C and washed successively 
with 50 ml of Buffer B and 50 ml of Buffer C. The final cell suspension in Buffer 
C was counted under a microscope with a hemocytometer. Ten fxl of the cell 
suspension were added to 190 fd of a trypan blue solution [150 mg trypan blue 
(Sigma) dissolved in 100 ml PBS] and an aliquot was applied to the hemocytometer 
after mixing. Since dead cells are stained blue in the trypan blue solution, they 
could be differentiated from the viable ones. Under these conditions, the number of 
dead cells was generally less than 5 % of the total. The number of viable cells (y) 
was counted. The viable cell concentration of the original cell suspension was then 
calculated by the following equation: 
number of viable cells (/ml) = y x 20 (dilution factor) x 10
4 
The cell suspension was diluted to give the appropriate cell numbers (0.5 - 1 
X 10
7
 cells/ml for Balb/c mice or 1.5 - 2 x 10^  cells/ml for guinea pigs) by adding 
Buffer C. 
2.2.2.2 PREPARATION OF WORKING SOLUTIONS 
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(1) 10 jbiM l-0-Alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (PAF) 
5 mg of PAF (Sigma) was dissolved in 1 ml of absolute ethanol to give a 
stock concentration of 9.5 mM. This stock solution was diluted to 10 /xM with 
Buffer C. 






0.1 mCi of [
3
H]-PAF (specific activity: 56 - 60 Ci/mmol, NEN) in 1 ml of 
absolute ethanol was diluted to the appropriate concentrations with Buffer C. 
2.2.2.3 ASSAY OF [%]-PAF BINDING 
One hundred of cell suspension were incubated with 100 /zl of 10 nM 
[^ H]-PAF and test drugs in a final volume of 0.5 ml Buffer C at room temperature 
(19.5 - 21°C) for 1 h. Nonspecific binding was defined with 2 fiM PAF. Specific 
binding was calculated by subtracting nonspecific binding from total binding. The 
reaction was terminated by rapid filtration using a Brandel cell harvester (Brandel 
Co., U.S.A.) through Whatman GF/B glass fibre filters which had been presoaked 
in Buffer A for 1 h. Filters were washed with 3 x 4 ml of ice-cold 50 mM 
Tris.HCl, pH 7.4. The filters were dried and radioactivity was measured by liquid 
scintillation spectrometry. 
Scatchard analysis was performed with 0.0195 nM to 10 nM pH]-PAF. 
Nonspecific binding in the saturation experiments was defined with 10 jjM PAF. 
2.2.3 [
3
H]-PAF BINDING TO RESIDENT PEC 
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2.2.3.1 PREPARATION OF RESIDENT PERITONEAL 
MACROPHAGES 
Peritoneal exudative cells were prepared as described in section 2.2.2.1 
from animals received no thioglycollate pretreatment. The cell suspension was 
diluted to 1 x 10
7
cells/ml with Buffer C. 
2.2.3.2 PREPARATION OF WORKING SOLUTIONS 
(1) 5 fiM PAF 
The 9.5 mM stock solution of PAF was diluted to 5 pM with Buffer C. 
(2) 5 nM [
3
H]-PAF 
The stock solution of [
3
H]-PAF was diluted to 5 nM with Buffer C. 
2.2.3.3 ASSAY OF [3H]-PAF BINDING 
One hundred /xl of 5 nM [
3
H]-PAF were added to 1.25 - 10 x 10
6
cells in a 
final volume of 2.5 ml of Buffer C and incubated at room temperature for 1 hr. 
Nonspecific binding was defined with 200 nM PAF. The reaction was terminated as 
described in section 2.2.2.3. 
2.2.4 PREPARATION OF DRUGS 
BN52021 & BN50739 were gifts from Dr. P.Braquet (Institute Henri 
Beaufau, Le Plessis, France) and prehispanolone and its derivatives were prepared 
from Leonurus heterophvllus by Mr. P.M.Hon and Mr. Y.He of C.M.M.R.C. 
41 
(C.U.H.K.). Drugs were dissolved in DMSO and diluted with Buffer C to give a 
final concentration of 1.8 % DMSO. The same concentration of DMSO was 
included in the controls for comparison. 
2.2.5 DATA ANALYSIS 
Results are presented either as percentage of specific binding or IC50S. 




Specific binding = Total binding - nonspecific binding 一 
% of specific specific binding in the presence of drug 
binding = — X 100% 
specific binding in the presence of vehicle 
2.3 MEASUREMENT OF INOSITOL PHOSPHATES 
2.3.1 PREPARATION OF REAGENTS 
(1) RPMI-1640 Medium 
RPMI-1640 medium contain Lcglutamine and 25 mM Hepes (catalog no. R 
4130) was purchased from Sigma Chemical Go (St.Louis，U.S.A.). Each package 
of the RPMI-1640 medium was made up to one litre with double-distilled water. 
Sodium bicarbonate (2.1 g) and glucose (3 g) were added and the pH was adjusted 
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with NaOH to 7.2. The solution was sterilized by passing through a millipore filter 
(0.2 fxm, Schleicher & Schwell) under suction and stored at 4°C. 
(2) Complete RPMI-1640 Medium (CM) 
Five ml of a penicillin (10,000 units/ml) and streptomycin (10,000 /xg/ml) 
solution (GIBCO) and 5 ml of a 200 mM L-glutamine solution (GIBCO) were 
added to 490 ml of sterilized RPMI-1640 medium. Hence, the final concentrations 
of supplements were : 100 units/ml of penicillin, 100 fig/ml of streptomycin and 2 
mM L-glutamine. 
(3) Complete RPMI-1640 Medium containing 10 % Fetal Calf Serum (10 % 
FCS CM) 
Fifty ml fetal calf serum (GIBCO), 5 ml of a penicillin (10,000 units/ml) 
and streptomycin (10,000 鮮g/ml) solution and 5 ml of 200 mM L-glutamine 
solution were added to 440 ml of sterilized RPMI-1640 medium. 
(4) Hank's Balanced Salt Solution (Hank's BSS) 
Hank's BSS containing 137 mM NaCl, 1.36 mM CaCl2.2H20, 0.88 mM 
MgS04.6H20, 5.4 mM KC1, 0.7 mM KH2P04, 15 mM NaHC03 and 11 mM 
glucose was adjusted to pH 7.5 and stored at 4°C. 
(5) Hank's Balanced Salt Solution with 0.25 % BSA [Hank's BSS (0.25 % 
BSA)] 
• .,‘j . 
Bovine serum albumin (250 mg) was dissolved in 100 ml of Hank's BSS. 
2.3.2 DOWEX COLUMN PREPARATION 
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Inositol phosphates were separated by anion-exchange chromatography using 
Dowex columns. Dowex resin (Bio-rad AG 1-X8, formate form, 200-400 mesh) 
was immersed in distilled water overnight and washed with five bed volumes of 
distilled water. The washed resin was resuspended in an equal volume of distilled 
water. Approximately 1.5 ml of the Dowex suspension was added to a column (1 x 
5 cm, Bio-rad) to give a resin bed of 1.5 cm in height. The column was washed 
twice with 5 ml of distilled water and ready for sample loading. 
2.3.3 CELL PLATING IN 24-WELL PLASTIC TRAYS 
TG- or resident-PEC were resuspended in CM and counted as described in 
section 2.2.2.1. The cell suspension was diluted to 1.5 - 2 x 10^ cells/ml by adding 
the appropriate volume of CM. One ml of the cell suspension was added to each 
well of a 24-well flat-bottomed plastic tray (Corning, U.S.A.). The 24-well plates 
were incubated in a humidified incubator under 5 % CC^  95 % air at 37°C for 2-3 
h to allow the macrophages to form a monolayer of adherent cells. Non-adherent 
cells were removed by gentle washing with 2 x 1 ml of Hank's BSS. 
2.3.4 DETERMINATION OF TOTAL INOSITOL PHOSPHATES 
The hydrolysis of prelabeled polyphosphoinositides induced by PAF was 
monitored by measuring the accumulation of [^ H]-inositol phosphates (IPs) 
J 
according to the procedure described by Downes and co-workers (1986) with some 
modifications. 
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Phosphoinositides (PI) were labeled by incubating cells in 24-well trays at 
370c in an incubator for 19 h with 3.5 - 4 ^ Ci/ml of [^ H]-inositol (Amersham, 
specific activity ; 17.5 - 18.2 Ci/mmol) in 10 % FCS CM. Extracellular [
3
H]-
inositol was then washed away and cells were equilibrated in Hank's BSS for 30 
min. To amplify the PI hydrolysis signal, cells were preincubated in 0.5 ml of 
Hank's BSS (0.25 % BSA) containing 10 mM LiCl for 15 min. Various test drugs 
in Hank's BSS (0.25 % BSA) containing 10 mM LiCl were then added and the 
cells were incubated at 37°C for 1 h. Reaction was terminated by discarding the 
medium and adding 1 ml of ice-cold 5 % perchloric acid (HCIO4). Cells were kept 
on ice for 30 min. The supernatant was then transferred to a glass test tube. To 
extract the perchloric acid, 1 ml of a mixture of trichlorotrifluoroethane (Sigma) 
and tri-n-octylamine (Sigma) (1:1，v/v) was added, followed by 100 jA of 100 
mM EDTA. The mixture was vortexed vigorously for 3 min and then centrifuged at 
110 g for 1 min at room temperature. The upper aqueous layer was collected and 
diluted to 5 ml with distilled water. 
2.3.5 COLUMN SEPARATION 
The sample was adjusted to pH 6 - 7 with 50 mM NaOH and then applied to 
a Dowex (AG 1-X8) column. To remove free [
3
H]-inositol, the column was 
washed with 2 x 5 ml of distilled water. Glycerol-phosphoinositol was eluted by 
adding 2 x 5 ml of a mixture of 60 mM sodium formate/5 mM sodium tetraborate. 
Total [^ H]-inositol phosphates were eluted by adding 5 ml of a mixture of 1 M 
ammonium formate/0.1 M formic acid. Radioactivity in the fractions was 
determined by liquid scintillation spectrometry. 
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The column was regenerated by adding 10 ml of a mixture of 2 M 
ammonium formate/0.1 M formic acid and then washed with 10 ml of distilled 
water. 
2.3.6 DETERMINATION OF INOSITOL TRISPHOSPHATE (IP3) 
The accumulation of IP3 induced by PAF was measured according to the 
procedure of Huang and Downes (1988) with some modifications. 
Cells were labelled with 8 /xCi/ml of [
3
H]-inositol for 19 h at 37°C in an 
incubator. Cells were washed and pre-equilibrated in Hank's BSS (0.25 % BSA) for 
30 min. PAF (100 nM) in 1 ml Hank's BSS (without LiCl) was added aM cells 
were incubated at 37°C for an indicated period. Reaction was terminated by adding 
0.5 ml of an ice-cold 5 % perchloric acid. Perchloric acid was extracted and 
samples neutralized as previously described (section 2.3.4). The samples were then 
applied to Dowex anion-exchange columns. [^ H]-inositol was eluted with 4 x 5 ml 
of distilled water. Glycerol-phosphoinositol was eluted with 4 x 5 ml of a mixture 
of 60 mM sodium formate/5 mM sodium tetraborate. pH]-inositol monophosphate, 
bisphosphate and trisphosphate were eluted with 4 x 5 ml of a mixture of 200 mM 
ammonium formate/100 mM formic acid, 400 mM ammonium formate/100 mM 
formic acid and 800 mM ammonium formate/100 mM formic acid, respectively. 
Radioactivity in these fractions was determined by liquid scintillation spectrometry. 
2.4 MEASUREMENT OF INOSITOL PHOSPHATE ACCUMULATION 
AFTER PROLONGED PMA PRETREATMENT 
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2.4.1 PREPARATION OF PHORBOL - 12 - MYRISTATE - 13 - ACETATE 
(PMA) SOLUTIONS 
(1) PMA (Sigma) was dissolved in DMSO to give a stock concentration of 10 
mM and stored at -20°C. 
(2) The stock solution was diluted with 10 % FCS CM to give a final 
concentration of 10 ^ cM PMA. 
2.4.2 PRETREATMENT OF CELLS WITH PMA 
Cells were cultured on 24-well plastic plates as described in section 2.3.3. 
Five hundred fd of a PMA working solution (10 ^ M) was added to each well and 
the cells were returned to the incubator. The measurement of total inositol 
phosphates was made after cells had been pretreated with 10 fiM PMA for 19 h at 
37°C. 
2.5 DETERMINATION OF SUPEROXIDE ANION PRODUCTION 
2.5.1 PREPARATION OF DRUGS 
BN50739 & LC-5507 were dissolved in DMSO and then diluted with 
Hank's BSS (0.25 % BSA). To control for the effect of solvent, all assays were 
done in the presence of 0.1 % DMSO. 
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2.5.2 ASSAY OF SUPEROXIDE ANION PRODUCTION 
The respiratory burst of peritoneal macrophages was measured as superoxide 
(C>2-)_mediated ferricytochrome C reduction. Cells were cultured on 24-well plastic 
plates as described in section 2.3.4 and were equilibrated in Hank's BSS for 15 
min. Various test drugs or the appropriate vehicles in Hank's BSS (0.25 % BSA) 
containing 80 弘M cytochrome C (Sigma) in a final volume of 1 ml were added and 
cells were incubated at 37°C for 1 h. The supernatant was collected, centrifuged at 
110 g for 5 min at 4°C and the absorbanee was measured at 550 nm using a 
spectrophotometer (Hitachi). Blanks contained 80 U/ml superoxide dismutase which 
removed any superoxide formed and served to control for the reduction of 
cytochrome C induced by agents other than O2". 
2.5.3 DATA ANALYSIS 
Absorbanee coefficient of cytochrome C is 21.1 mmol/l"^ cm"^  (Urbaniak et 






 cells/h)= — 
21.1 x Cell Number (lxlO
6
) 
2.6 STATISTICAL METHOD 
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All results were expressed as the arithmatic mean 士 standard deviation. The 
significance of difference between control and test groups was assessed by the 
Student's t-test. 
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CHAPTER THREE. RESULTS 
3.1 [3H]-PAF BINDING TO TG-PEC 
3.1.1 GENERAL PROPERTIES 
The binding of [
3
H]-PAF to guinea pig TG-PEC was both time and 
temperature-dependent. When the assay was performed at 0°C, the non-specific 
binding did not change with time but it took two hours for the specific binding to 
reach a plateau (Fig. 3.1). At 20°C, both specific and non-specific binding of 
[3h]-PAF showed no significant change between 30 and 120 min of incubation 
(Fig. 3.2). At 37°C, specific binding of [
3
H]-PAF did not change significantly 
between 30 and 120 min, however, both the non-specific and total binding 
increased steadily with increasing incubation time (Fig. 3.3). The equilibrium 
specific binding of [^ H]-PAF to guinea pig TG-PEC at 37°C was approximately the 
same as that at 20°C but significantly higher than that at 0°C. 
No significant specific binding of [^ H]-PAF to TG-PEC from Balb/c mice 
can be detected at 0°C • Specific binding of [^ H]-PAF, however, can be obtained 
when the cells were incubated at 20°C (Fig. 3.4). 
The binding of [
3
H]-PAF at 20°C to murine and guinea pig TG-PEC was 
proportional to the cell number used (Fig. 3.5 and 3.6). The specific binding 
increased linearly when the cell number was increased from 0.5 to 2.5 x 10^  cells. 




_ _ _ o -
0^ — 一 
Q 8000'— ^ ^ ^ ^ ^ 
宁 6000 — 
I r ,, 
厂{ ,| M 丨 ^ ^ 
co ~~言 
I 1 A 
^ 4000 — _ _ _ _ _ 
o 
a a - — ^ ；3 2000 — 
•r-4 
CQ 
o-l 1 1 1 
30 60 90 120 
Time (min) 
Fig. 3.1 
Time course of [^ EQ-PAF (2nM) binding to guinea pig TG-PEC at 0°C. ( o ) and ( 0 ) represent the 
binding of [
3
H]-PAF in the absence and presence of 2 juM PAF, respectively.(厶）represents the specific 
binding calculated by subtracting the nonspecific binding from the total binding. Data are the means of 
duplicate determinations which varied less than 10 %. 
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Fig. 3.2 
Time course of [
3
H]-PAF (2 nM) binding to guinea pig TG-PEC at 20°C. ( o ) and (•) represent the 
binding of [^ H]-PAF in the absence or presence of 2 jiM PAF respectively. (^) represents the specific 
binding calculated by subtracting (• ) from ( o ). Data are the means of duplicate determinations which 
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Fig 3.3 
Time course of [
3
H]-PAF (2 nM) binding to guinea pig TG-PEC at 37°C. ( o ) and (•) represent the 
binding of [^ HJ-PAF in the absence or presence of 2 juM PAF, respectively. (A) represents the specific 
binding calculated by subtracting (• ) from ( o ). Data are the means of duplicate determinations which 
varied less than 10 %. 
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Fig. 3.4 
Time course of [
3
H]-PAF (2 nM) binding to Baib/c mice TG-PEC at 20°C. ( o ) and (• ) represent 
the binding of [
3
H]-PAF in the absence and presence of 2 juM PAF, respectively.(厶)represents the 
specific binding calculated by substracting ( • ) from ( o ). Data are the means of duplicate 
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Effect of cell number on the binding of [
3
H]-PAF to Balb/c mice TG-PEC. Binding of 2 nM [
3
H]-
PAF to different cell numbers of TG-PEC from Balb/c mice was studied at 20°C for 1 h. ( o ) and ( •) 
represent the binding of [
3
H]-PAF in the absence and presence of 2 |iM PAF, respectively. Data are the 
means of duplicate determinations which varied less than 5 % from a typical experiment. Similar results 
were obtained in two separate experiments. 
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Fig 3.6 
Effect of cell number on the binding of [
3
H]-PAF to guinea pig TG-PEC. Binding of 2 nM [
3
H]-PAF 
to different cell numbers of TG-PEC from guinea pigs was studied at 20°C for 1 h. ( o ) and ( •) 
represent the binding of [
3
H]-PAF in the absence and presence of 2 juM PAF, respectively. Data arc the 
means of duplicate determinations which varied less than 5 % from a typical experiment. Similar results 
were obtained in two separate experiments. 
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0.5 - 1 x 10
6
 and 1.5 - 2 x 10
6
 TG-PEC from Balb/c mice and guinea pigs, 
respectively, were used in all subsequent experiments. 
3.1.2 STEREOSPECIBICITY OF PAF RECEPTOR 
When the effects of the D- and L-stereoisomers of PAF on specific [^ H]-
PAF binding to TG-PEC of Balb/c mice were examined, it is clear that L-PAF was 
a more effective inhibitor than D-PAF (Fig. 3.7). The same result was obtained 
when the binding was performed at 0°C and 20°C. This result supports the notion 
that the PAF receptors on TG-PEC are stereoselective for PAF and that the 
naturally occurring L-PAF is the preferred stereoisomer. 
3.1.3 COMPARISON OF [
3
H]-PAF BINDING TO TG-PEC AND TG-PM 少 
FROM Balb/c MICE 
Peritoneal macrophages (TG-PMO) can be isolated by their adhesive 
property. Macrophages, but not other cells in the peritoneal lavage, adhered to the 
culture dish within 2 h at 37°C. When the TG-PEG (mixed), nonadhesive TG-PEC 
(nonadhesive) and TG-PMO (adhesive) were assayed for [^ H]-PAF binding at 20°C 
for 1 h, it was found that both TG-PEC and TG-PMO displayed similar magnitude 
of specific binding (Fig. 3.8). 
3.1.4 INHIBITION OF SPECIFIC BINDING OF [
3
H]-PAF TO MURINE 
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Fig. 3.7 
Effect of D-PAF and L-PAF on the binding of [3H]-PAF to Balb/c mice TG-PEC. 2 x 106 cells were 
incubated with 2 nM [
3
H]-PAF at 0°C for 2 h (Left panel) or at 20°C for 1 h (Right panel), a, represents 
the total binding, b and c, represent the binding in the presence of 2 juM D-PAF and 2 juM L-PAF, 
respectively. Data are the means of duplicate determinations which varied less than 10 % from a typical 
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Fig. 3.8 
Comparison of binding of [
3
H]-PAF to mixed, non-adhesive and adhesive Balb/c TG-PEC. The 
peritoneal lavage (mixed) cells in CM were incubated at 37°C "for 2-3 h and peritoneal macrophages 
(adhesive cells) were adhered to the bottom of culture dish. The non-adhesive cells in the CM were 
collected. The cells (0.5 x 10
6
 cells) were incubated with 2 nM [
3
H]-PAF at room temperature for Ih. a 
and b represent the binding in the absence and presence of 2 juM PAF, respectively, c, represents the 
specific binding which was calculated by subtracting b from a. Data are the means of duplicate 
determinations which varied less than 5 % from a typical experiment. Similar results were obtained in 
four separate experiments. 
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The specific binding of [
3
H]-PAF to TG-PEC from Balb/c mice was 
inhibited by PAF in a concentration-dependent manner (Fig. 3.9). When the 
displacement curves were analysed by the Hill plot, the IC50 (concentration which 
inhibited 50 % of specific binding) of PAF was estimated to be 3.8 土 0.9 nM and 
the pseudo-Hill coefficient (rjH) was 1.34 士 0.04 (means 士 S.D., n=3). PAF also 
inhibited the specific binding of [^ H]-PAF to guinea-pig TG-PEC with a somewhat 
higher potency, IC50 = 1.43 士 0.26 nM and ^ =0.7 士 0.09 (means 土 S.D., 
n=3) (Fig. 3.10). 
3.1.5 EFFECTS OF PAF ANTAGONISTS ON THE BINDING OF [
3
H]-PAF 
TO TG-PEC FROM Balb/c MICE AND GUINEA PIGS 
The effects of several PAF antagonists, namely BN 52021, BN 50739, 
prehispanolone (LC-5504) and its derivatives, LC-5506, LC-5507, LC-5508 and 
LC-5509 on the specific binding of [
3
H]-PAF to TG-PEC isolated from Balb/c 
mice and guinea pigs were studied. These compounds were able to inhibit specific 
[^ H]-PAF binding in a concentration-dependent manner. Typical displacement 
curves for BN52021, BN50739, LC-5504 and LC-5507 in murine and guinea pig 
TG-PEC are shown in Fig. 3.11 and Fig. 3.12, respectively. The displacement 
curves were generally more shallow in the case of TG-PEC from the Balb/c mice 
than that from the guinea pigs. When the inhibitory potencies of these PAF 
antagonists were compared on the basis of their IC50S, the rank order of potencies 
was BN50739 >> LC-5507 > LC-5508 >= LC-5509 > LC-5506 >= LC-
5504 > =BN52021 in murine and BN50739 > > LC-5507 > LC-5509 > 
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Fig. 3.9 
Inhibition of specific binding of [
3
H]-PAF to Balb/c mice TG-PEC by PAF. Binding of 2 nM [
3
H]-
PAF in the presence of different concentrations of PAF was performed at 20°C for 1 h. The nonspecific 
binding of [^ H]-PAF was defined by 2 juM PAF. Data are the means 土 S.D. of triplicate determinations 
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Fig. 3.10 
Inhibition of specific binding of [
3
H]-PAF to guinea pig TG-PEC by PAF. Binding of 2 nM [
3
H]-PAF 
in the presence of different concentrations of PAF was performed at 20°C for 1 h. The nonspecific 
binding of [^ H]-PAF was defined by 2 jliM PAF. Data are the means 土 S.D. of triplicate determinations 
from a typical experiment. Similar results were obtained in three separate experiments. 
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Fig. 3.11 
Effect of PAF antagonists on the binding of [
3
H]-PAF to TG-PEC of Balb/c mice. Binding of 2 nM 
[
3
H]-PAF in the presence of BN5201 ( o )，BN50739 (•), LC-5504 (A) or LC-5507 (口）was performed 
at 20°C for 1 h. Data are the means of duplicate determinations which varied less than 10 % from a 
typical experiment. Similar results were obtained in three separate experiments. 
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Fig.3.12 
Effect of PAF antagonists on the binding of [
3
H]-PAF to guinea pig TG-PEC. Binding of 2 nM [
3
H]-
PAF in the presence of BN52021 ( o )，BN50739 (• )，LC-5504 (厶）or LC-5507 (A) was performed at 
20°C for 1 h. Data are the means 土 S.D. (indicated by bars) of separate three experiments performed in 
duplicate. 
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(Table 3.1). These patterns differ significantly from that observed for the 
inhibitory effects of the same compounds on specific [
3
H]-PAF binding to rabbit 
platelets, where BN50739 >> LC-5507 > BN52021 >= LC-5509 > LC-5506 
> =LC-5504 > = LC-5508 (Table 3.1). 
Moreover, these compounds, with the exception of BN50739, were 
generally 3-10 fold more potent against [
3
H]-PAF binding to platelets than to 
murine and guinea pig TG-PEC (Table 3.1). BN50739, on the other hand, was 
actually more active as an inhibitor against [^ H]-PAF binding to guinea pig TG-
PEC than to rabbit platelets. 
While LC-5507 and LC-5508 have similar inhibitory potency against [
3
H]-
PAF binding to TG-PEC of both Balb/c mice and guinea pigs, BN52021, 
BN50739, LC-5504, LC-5506 and LC-5509 were all clearly less active in inhibiting 
[
3
H]-PAF binding to murine TG-PEC. 
3,1.6 SCATCHARD ANALYSIS OF [
3
H]-PAF BINDING TO MURINE AND 
GUINEA PIG TG-PMO 
The saturation analyses of [^ H]-PAF binding to murine and guinea pig TG-
PM^  are shown in Fig. 3.13 and Fig. 3.14. Specific binding of pH]-PAF to 
murine and guinea pig TG-PMO was saturable and reached a plateau at 2.5 nM and 
1.25 nM pH]-PAF, respectively. The nonspecific binding, on the other hand, was 
linear over the concentration range of [^ H]-PAF tested. Scatchard analyses of 
specific [3h]-PAF binding to murine and guinea pig TG-PMO revealed the 
presence of a single binding site for [^ H]-PAF with an apparent Kd of 1.6 and 0.4 
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BN52021 4.8 士 1.6 189.6 士 20.2 ** 31.5 土 18.5 * 
(r| H = 1 土 0.4) (r| H= 1.0 士 0.2) 
BN50739 0.03 土 0.006 0.10 ±0.04* 0.017 土 0.005 * 
(r|H=0.8 土 0.3) (r|H=l.l 士 0.3) 
LC-5504 14.1 士 7.9 171.2 士 8.7 ** 40.0 士 11.9 * 
(T1H=0.7 土 0.3) (r|H=1.3 ± 0.2) 
LC-5506 13.4 土 7.4 144.4 土 25.5 ** 54.2 土 18.5 ** 
(T| h = 0 . 6 ± 0 . 1 ) ( r | H = 1 .1 士 0 . 2 ) 产： 
LC-5507 1.2 土 0.7 8.1 ±2.9 8.0 ±2.1 ** 
(R|H=0.6 ±0.06) 01 H= 1.2 土 0.3) 
LC-5508 14.2 士 7.7 37.0 士 11.5* 35.3 ±11.2 * 
(R|H=1.2 土 0.4) (T]H=1.2 土 0.06) 
LC-5509 5.7 土 2.7 56.1 ±4.1 ** 18.2 土 7.2 * 
(T1 h=0.9 土 0.4) (r| H= 1.2 土 0.1) 
a- [
3
H]-PAF (2 nM) binding to intact cells was measured at 20°C for 1 h. Non-specific binding was 
defined with 2 mM PAF. 
b. IC5Q is the concentration of drug which inhibits 50% of specific binding, 
c. Data from Lee, C.M., et al (1991). 
d. Data are the means 土 S.D. of performed in duplicate three separate experiments. 
* p < 0.05 when compared with data in rabbit platelets using Student's t-test. 
** p < 0.01 when compared with data in rabbit platelets using Student's t-test. 
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Satuation analysis of [
3
H]-PAF binding to Balb/c mice TG-PM<J>. Balb/c TG-PMO were incubated 
with 0.0195 nM to 10 nM [
3
H]-PAF at 20°C for 1 h. Non-specific binding was defined with 10 JLIM PAF. 
(o ) and (• ) represent [^ H]-PAF binding in the absence and presence of 10 JLIM PAF, respectively. (A) 
represents the specific binding calculated by substracting (•) from ( o ). Data are the means of triplicate 
determinations which varied less than 10 % from a typical experiment. Similar results were obtained in 
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Saturation analysis of [^ H]-PAF binding to guinea pig TG-PMO. Guinea pig TG-PMO were 
incubated with 0.039 nM to 10 nM [
3
H]-PAF at 20°C for 1 h. Non-specific binding was defined with 10 
juM PAF. ( 0 ) and ( • ) represent [^ H]-PAF binding in the absence and presence of 10 JLIM PAF, 
respectively. (A) represents the specific binding calculated by substracting (•) from ( 0 ). Data are the 
means 土 S.D. of triplicate determinations. 
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nM and a Bmax of 101 and 37.0 fmol of receptor/10
6
 cells, respectively (Fig. 3.15 
and 3.16). The Hill coefficients for the saturation curves were 0.96 and 0.9 for 
murine and guinea pig TG-PMo, indicating the absence of co-operativity in [%]-
PAF binding. 
3.2 SUPEROXIDE ANION PRODUCTION IN PERITONEAL 
MACROPHAGES 
3.2.1 SUPEROXIDE ANION PRODUCTION INDUCED BY PAF IN 
MURINE AND GUINEA PIG TG-PMO 
Superoxide (O2") production induced by PAF was studied in TG-PM<s> from 
Balb/c mice (Fig. 3.17) ^ nd guinea pigs (Fig. 3.18). PAF induced O2' production 
from guinea pig TG-PMo in a dose-dependent manner with an EC50 (concentration 
of drug which produce 50% of the maximal response) of 1.4 土 1 nM (mean 士 
S.D., n=4). However, no significant stimulation of O2" formation was obtained 
from murine TG - PMO when they were incubated with 10"^  to 10"^  M PAF. 
3.2.2 EFFECT OF PMA ON SUPEROXIDE PRODUCTION IN MURESfE 
AND GUINEA PIG TG-PM^ 
PMA, a PKC activator, on the other hand, can induce O2" production in 
TG-PMO from both Balb/c mice (Fig. 3.17) and guinea pigs (Fig. 3.19), and the 
maximal response was 4 fold higher in the latter case. At 1 /xM, PMA induced O2" 
production in murine TG-PMO from 0.18 to 3.56 nmol/10
6
cells/h and from 0.29 to 
14.1 nmol/10^ cells/h in guinea pig TG-PMo. Moreover, PMA was a more potent 
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Fig.3.15 
Scatchard analysis of specific pH]-PAF binding to Balb/c mice TG-peritoneal macrophages. Data 
are the means of triplicate determinations from a typical experiment. Kd = 1.6 nM, Hill coefficient = 1， 
Bmax = 101 fmoles/lO c^ells. Similar results were obtained in three separate experiments. 
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Scatchard analysis of specific [^ H]-PAF binding to guinea pig TG-peritonea macrophages. Data are 
the means of triplicate determinations. Kd = 0.4 nM, Hill coefficient = 0.9，Bmax = 37 fmoles/lO c^ells. 
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Fig.3.17 
Superoxide Production induced by PMA, A23187 and PAF,in Balb/c mice TG-PM巾.Cells were 
incubated with various drugs at 37°C for 1 h. ( o ) PMA, (•) A23187 and (A) PAF. Data are the means 
of duplicate determinations which varied less than 10 % from a typical experiment. Similar results were 
obtained in (n) separate experiments, PMA (n=4), A23187 (n=2)，PAF (n=4). 
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Fig.3.18 
Superoxide Production induced by PAF in guinea pig TG-PMO. Cells were incubated with indicated 
concentrations of PAF at 37°C for 1 h. Data are the means of duplicate determinations which varied less 
than 5 % from a typical experiment. Similar results were obtained in eight separate experiments. 
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Fig.3.19 
Effect of PMA on superoxide production in guinea pig TG-PM<I>. Cells were incubated with indicated 
concentrations of PMA at 37°C for 1 h. Data are the means of duplicate determinations which varied less 
than 5 % from a typical experiment. Similar results were obtained in five separate experiments. 
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stimulator in guinea pig than in murine TG-PM否 and the EC50 of PMA was 2.4 
士 0.9 nM and 12.7 土 5.8 nM, respectively. 
In the guinea pig TG-PM ,^ PAF induced O2" production was found to be 
additive with 1 nM PMA (Fig. 3.20) and the EC50 of PAF was not significantly 
altered by the presence of 1 nM PMA (control, 1.4 nM; in the presence of PMA, 




 M) was equally ineffective in 
stimulating O2" production in the presence or absence of 1 nM PMA (Fig. 3.21). 
3.2.3 EFFECT OF CALCIUM IONOPHORE ON SUPEROXIDE 
PRODUCTION IN MURINE AND GUINEA PIG TG-PMO 
A23187, a calcium ionophore, did not stimulate superoxide production 
significantly in TG-PM否 from Balb/c mice and guinea pigs (Fig. 3.17 and 3.22). 
Superoxide production in murine TG-PM^  was 0.29 土 0.07 and 0.18 士 0.09 
nmol/10^ cells/h in the presence and absence of 10 fiM A23187, respectively. 
Similar result was observed in guinea pig TG-PM$. Moreover, the superoxide 
production induced by 10 nM PAF in guinea pig TG-PM^  was not affected by the 
presence of 10 弘M A23187 (Fig. 3.22). 
3.2.4 EFFECT OF PAF ANTAGONISTS ON PAF-INDUCED SUPEROXIDE 
PRODUCTION IN GUINEA PIG TG-PM<I> 
Two PAF antagonists, BN50739 and LC-5507, were studied for their effects 
on superoxide production induced by 2 nM PAF in guinea-pig TG-PM .^ They 
were able to inhibit the PAF-induced O2" production in a concentration - dependent 
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Fig.3.20 
Superoxide Production induced by PAF in the presence of 1 nM PMA in guinea pig TG-PMO. Cells 
were incubated with indicated concentrations of PAF in the absence ( 0 ) or presence (• ) of 1 nM PMA 
at 37°C for 1 h. The basal and 1 nM PMA-stimulated superoxide production were 1.46 士 0.03 and 6.08 士 
0.26 nmole/10
6
 cells, respectively. Data are the means of duplicate determinations which varied less than 
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Fig.3.21 
Superoxide Production induced by PAF in the presence of 1 nM PMA in Balb/c mice TG-PMO. 
Cells were incubated with indicated concentrations of PAF in the absence ( o ) or presence (• ) of 1 nM 
PMA at 37°C for 1 h. The basal and 1 nM PMA stimulated superoxide production were 0.16 土 0.06 and 
0.39 土 0.19 nmole/106 cells respectively. Data are the means of duplicate determinations which varied 
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Effect of calcium ionophore on superoxide production induced by 10 nM PAF in guinea pig TG-
PM<I>. Cells were incubated with various drugs at 37°C for 1 h. a, control; b, 10 juM A23187; c, 10 nM 
PAF; and d, 10 juM A23187 + 10 nM PAF. 
Data are the means of two separate experiments performed in 
duplicate which varied less than 5 % • 
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manner (Fig. 3.23). BN50739, with an IC50 of 0.003 fiM, was a much more 
potent PAF antagonist than LC-5507 (IC50 = 9.3 pM). While LC-5507 displayed 
very similar potency as inhibitor of specific [^ H]-PAF binding and PAF-induced 
O2" formation, BN50739 was 6 fold more active as an inhibitor of PAF-induced 
O2" formation than specific [
3
H]-PAF binding (Table 3.2). 
3.3 PHOSPHOLIPASE C • PHOSPHATIDYLINOSITOL SYSTEM IN 
PERITONEAL MACROPHAGES 
3.3.1 EFFECT OF PAF ON THE ACCUMULATION OF INOSITOL 
PHOSPHATES IN THE ABSENCE OF LiCl 





H]-IP3 but not [
3
H]-glycerol phosphoinositol in TG-PM$ 
from Balb/c mice and guinea pigs (Fig. 3.24 and 3.26). In murine peritoneal 
macrophages, [^ H]-IP3 formation increased with time and reached a peak at 30 
seconds and then started to decrease with longer incubation (Fig. 3.25). The levels 
of IP and IP2, on the other hand, tended to increase from 5 second to 1 min (Fig. 
3.24). In guinea pig TG-PM$, PAF induced [^ H]-IP3 formation was highest at 5 
seconds and decreased rapidly with larger incubation time (Fig. 3.27). The time-
course of production of [^ H]-IP and pH]-IP2 was, however, more comparable to 
that observed for TG-PM$ from Balb/c mice. 
3.3.2 EFFECT OF PAF ON THE ACCUMULATION OF INOSITOL 
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Fig.3.23 
Effect of PAF antagonists on the superoxide production induced by 2 nM PAF in guinea pig TG-
PM<I>. Cells were incubated with or without various PAF antagonists at 37°C for 1 h and superoxide 
production induced by 2 nM PAF was measured. BN50739 (o )，LC-5507 (•). Data are the means of two 
separate experiments performed in duplicate which varied less than 10 %. 
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3.2 Comparison of potencies of PAF Antagonists as inhibitors of specific [
3
H]-PAF binding and 
PAF-induced [^ H]-IPS accumulation and O2" formation in guinea pig TG-PEC 
IC50 _  A 
[
3
H]-PAF Binding厶 PAF-induced [^ H]-IPs Oo" Formation^  
accumulation
0 
BN52021 31.5 土 18.5 21.9 土 18.1 N.D. 
0? H =1 .0 土 0.2) (VH=°' 8 士 0 - 4 ) 
BN50739 0.017 士 0.005 0.007 0.003 : 
0?h=1.1±0.3) (%=1.0) (^ H=1.1) 
LC-5504 40.0 士 11.9 163.2 N.D. 
士 0.2) (t?h=1.5) 
LC-5507 8.0 士 2.1 26.7 土 13.9 9.3 
0^=1.2 土 0.3) 0^=0.8 土 0.2) (Vh=L2) 
a. IC5Q is the concentration of drug which inhibits 50% of specific binding. 
b. Data from Table 3.1 
c. [^ H]-IPs accumulation induced by 2 nM PAF was measured at 37°C for 1 h. Data are the 
means (土 S.D.) of two (BN50739, LC-5504) to three (BN52021, LC-5507) separate 
experiments performed in duplicate. 
d. 。2_ formation induced by 2 nM PAF was measured at 37°C for 1 h. Data are the means of two 
separate experiments performed in duplicate. 
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Fig.3.24 
Typical elution proHle of [
3
H]-inositol phosphates on an anion exchange column in Balb/c mice TG-
PEC. Reactions were terminated after the cells had been exposed to buffer (o-o) or 100 nM PAF for 5 
second (•), 15 seconds (A), 30 seconds (•)’ 1 min. (•) and 5 min. (•). 5 ml fractions were collected as 
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Fig.3.25 
Typical elution profile of [
3
H]-inositol phosphates on an anion exchange column in Balb/c TG-PEC. 
Reactions were terminated after the cells had been exposed to buffer (o"o) or 100 nM PAF for 30 seconds 
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Fig.3.26 
Typical elution profile of [
3
H]-inositol phosphates on an anion exchange column in guinea pig TG-
PEC. Reactions were terminated after the cells had been exposed to buffer (o-o) or 100 nM PAF for 5 
second (•), 15 seconds (厶)，30 seconds (•)，1 min (•) and 5 min (麗).5 ml fractions were collected as 
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Fig.3.27 
Typical eiution profile of pH]-inositoi phosphates on an anion exchange column in guinea pig TG-
PEC. Reactions were terminated after the cells had been exposed to buffer (o..o) or 100 nM PAF for 5 
second (•)，1 min (口) and 5 min (颶)• 5 ml fractions were collected as described in section 2.3. 
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3.3.2.1 TIME COURSE OF [
3
H]-INOSITOL PHOSPHATES 
ACCUMULATION INDUCED BY PAF IN TG-PMO 
In the presence of 10 mM LiCl, PAF (100 nM) induced a time-dependent 
accumulation of [
3
H]-IPs in TG-peritoneal macrophages of Balb/c mice at 37°C. 
As illustrated in Fig. 3.28, the level of [
3
H]-IPs increased rapidly after 5 min 
exposure to PAF and reached a plateau after 1 h (Fig. 3.28). Increasing the 
incubation time to 90 min. did not increase the level of pH]-IPs much further. 
Therefore, a 60 min incubation time was adopted in all subsequent experiments. 
3.3.2.2 EFFECT OF PAF ON THE ACCUMULATION OF [
3
H]-IPs IN 
TG-PMO FROM Balb/c MICE AND GUINEA PIGS 
PAF stimulated the accumulation of [^ H]-IPs in a dose-dependent manner in 
both murine and guinea pig TG-PMO (Fig. 3.29 and 3.30). The maximal response 
of pH]-IPs accumulation induced by PAF were obtained at 10 nM PAF for both 
species. PAF was a slightly more potent simulator of [^ H]-IPs accumulation in 
guinea pig peritoneal macrophages with an EC50 of 0.51 土 0.12 nM (means 士 
S.D., n = 3) than that in murine peritoneal macrophages, EC50 = 0.91 士 0.31 
nM (means 士 S.D., n = 3). 
3.3.2.3 EFFECT OF PAF ANTAGONISTS ON PAF-INDUCED [
3
H]-IPs 
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Fig.3.28 
Time course of [
3
H]-IPs accumulation induced by 100 nM PAF in Balb/c mice TG-PMO. Cells were 
prelabeled with 3.5~4.0 |nCi/ml of [
3
H]-inositol for 19 h. [
3
H]-IPs accumulation was performed at 37°C. 
Data are the means 土 S.D. of triplicate determinations from a typical experiment. Similar results were 
obtained in two separate experiments. 
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Fig.3.29 
Effect of PAF on the [
3
H]-IPs accumulation in Balb/c mice TG-PM<D. TC-PEC were prelabeled by 
incubation with 3.5 ~ 4 ^ Ci/ml of [
3
H]-inositol for 19 h. [
3
H]-IPs accumulation induced by PAF was 
performed at 37°C for 1 h. The basal level of [
3
H]-IPs was 277 土 18 dpm. Data are the means 士 S.D. of 
triplicate determinations from a typical experiment. Similar results were obtained in four separate 
experiments. 
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Fig.3.30 
Effect of PAF on the [
3
H]-IPs accumulation in guinea pig TG-PMO. TG-PEC were prelabeled by 
incubation with 3.5 〜4 jiCi/ml of [3H]-inositol for 19 h. [3H]-IPs accumulation induced by PAF was 
performed at 37°C for 1 h. The basal level of [
3
H]-IPs was 626 土 13 dpm. Data are the means 土 S.D. of 
triplicate determinations from a typical experiment. Similar results were obtained in 3 separate 
experiments. 
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Four PAF receptor antagonists, BN52021, BN50739, LC-5504 and LC-
5507 were found to decrease the [
3
H]-IPs formation induced by 2 nM PAF in a 
concentration-dependent manner in both murine and guinea pig TG-PM^  (Fig.3.31 
and 3.32). Their IC50S are shown in Table 3.2 and 3.3 in comparison with their 
IC50S as inhibitors of [
3
H]-PAF binding. It is clear that their potency in inhibiting 
[3h]-PAF binding correlated very closely with their potency in inhibiting PAF-
induced [3H]-IPS accumulation. The same is true for TG-PMo from both Balb/c 
mice and guinea pigs. 
3.3.2.4 EFFECT OF PMA ON PAF-INDUCED [
3
H]-IPs FORMATION 
IN TG-PM O FROM Balb/c MICE AND GUINEA PIGS 
PMA, a PKC activator, inhibited [^ H]-IPs accumulation induced by 10 nM 
PAF in both murine and guinea pig TG-PM<f (Fig. 3.33 and 3.34). The IC50 of 
PMA was 5.7 土 1.5 nM (means 士 S.D.，n = 3) and 1.4 nM (means of 2 Separate 
experiments performed in duplicate) in murine and guinea pig peritoneal 
macrophages, respectively, indicating that PMA was 4 times more potent in TG-
PMo from guinea pigs than Balb/c mice. 
3.3.2.5 EFFECT OF PROLONGED PMA PRETREATMENT ON PAF 
AND PMA INDUCED [
3
H]-IPs ACCUMULATION IN MURINE 
AND GUINEA-PIG TG-PM4> 
In order to down-regulate PKC in TG-PM$ of Balb/c mice and guinea pigs, 
cells were preincubated with 10 ^ M PMA for 19 h. 
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Fig.3.31 
Effect of PAF antagonists on PAF-induced [
3
H]-IPS accumulation in Balb/c mice TG-PMO. Cells 
were pretreated with various concentrations of BN52021 ( o )，BN50739 (• )，LC5504 (A) and LC5507 (A 
)for 15 min and then [
3
H]-IPs accumulation induced by 2 nM PAF was measured at 37°C for 1 h.. Data 
are the means 土 S.D. of three separate experiments performed in triplicate. 
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Fig.3.32 
Effect of PAF antagonists on PAF-induced pH]-IPs accumulation in guinea pig TG-PMO. Cells 
were pretreated with various concentrations of BN52021 ( o )，BN50739 (• )，LC-5504 (A) and LC-5507 
(A) for 15 min and then [^ H]-IPs accumulation induced by 2 nM PAF at 37°C for 1 h was measured. 
Data are the means 土 S.D. of in two (BN50739, LC-5504)-three (BN52021, LC-5507) separate 
experiments performed in deplicate. 
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Table 3.3 Comparison of potencies of PAF Antagonists as inhibitors of specific 
[
3
H]-PAF binding and PAF-induced [
3












BN52021 189.6 士 16.5 (r|H=1.2 土 0.4) 186.0 土 21.0 (riH=1.0 土 0.2) 
BN50739 0.10 ±0.04 (T1h二0.8 ±0.3) 0.10 土 0.12 (r|H=0.8 士 0.1) 
LC-5504 171.2 土 7 .1 (r|H=0.7 土 0.3) 181.8 (T]H=1.9，1-2) ,, 
LC-5507 8.1 土 2.4(riH=0.6 土 0.06) 12.9 ± 4.8 (T1H=0.8 土 0.06) 
a. IC50 is the concentration of drug which inhibits 50% of specific binding. 
b. Data from Table 3.1。 
c. [3H]-IPS accumulation induced by 2 nM PAF was performed by incubation at 
37°C for 1 h. Data are the means of 士 S.D. of triplicate determinations from 
three separate experiments (except LC-5504, n=2) performed in triplicate. 
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Fig.3.33 
Effect of PMA on [
3
H]-IPs accumulation induced by 10 nM PAF in Balb/c mice TG-PMO. [
3
H]-IPs 
accumulation induced by 10 nM PAF in the presence of various concentrations of PMA was meausred at 
37°C for 1 h. The level of [
3
H]-IPs induced by 10 nM PAF in the absence of PMA was 5005 土 362 dpm. 
Data are the means 土 S.D. of triplicate determinations from a typical experiment. Similar results were 
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Fig.3.34 
Effect of PMA on [
3
H]-IPs accumulation induced by 10 nM PAF in guinea pig TG-PMO. [
3
H]-IPs 
accumulation induced by 10 nM PAF in the presence of various concentrations of PMA was measured at 
37°C for 1 h. The level of [
3
H]-IPs induced by 10 nM PAF in the absence of PMA was 4053 士 dpm. 
Data are the means 士 S.D. of triplicate determinations from a typical experiment. Similar results were 
obtained in three separate experiments. 
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In murine TG-PM否，there was a 90 - 100 % increase of [3H]-IPs 
accumulation induced by 10 nM PAF after prolonged PMA pretreatment when 
compared with the non-PMA treated control group (Fig. 3.35). There was no 
inhibition of PAF-induced [
3
H]-IPs accumulation in the presence of 1 fiM PMA 
under these conditions, suggesting that PKC had been down-regulated by the 
prolonged PMA treatment. 
In TG-PM$ of guinea pigs, [
3
H]-IPs accumulation induced by 10 nM PAF 
was decreased from 4240 士 86 DPM to 1002 ±51 DPM after prolonged PMA 
pretreatment (Fig. 3.36). Moreover, there was a further decrease [
3
H]-IPs 
accumulation in the presence of 1 juM PMA, suggesting that the PKC in these cells 
had not been down-regulated by treatment with 10 /jlM PMA for 19 h. 
3.4 STUDIES OF PAF RECEPTORS ON RESIDENT PEC FROM Balb/c 
MICE 
3.4.1 BINDING OF 2 nM [
3
H]-PAF TO Balb/c MICE RESIDENT PEC 
Binding of 2 nM [
3
H]-PAF to Balb/c mice resident PEC was studied under 
the same radioligand binding assay condition as thioglycollate-elicited PEC (2 nM 
[
3
H]-PAF, 0.5 x 10
6
cells, 20°C, 60 min). There was no detectable specific 
binding of [^ H]-PAF to resident PEC when these cells were studied either as a 
mixture or as purified macrophages (Fig. 3.37). 
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Fig.3.35 
Effect of prolonged PMA pretreatment on [
3
H]-EPs accumulation induced by 10 nM PAF in Balb/c 
mice TG-PM<I>. Cells were pre-incubated with 3.5^ 4.0 juCi/ml [
3
H]-inositol in 10 % FCS CM with or 
without 10 nM PMA for 19 h. [
3
H]-IPs accumulation induced by drugs was measured at 37°C for 1 h. a, 
buffer control; b’ 10 nM PAF; c, 10 nM PAF and 1 juM PMA; d, 1 MM PMA. Data are the means 士 S.D. 
of triplicate determinations from a typical experiment. Similar results were obtained in two separate 
experiments. 
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Fig.3.36 
Effect of prolonged PMA pretreatement on [^ H]-IPs accumulation induced by 10 nM PAF in 
guinea pig TG-PMd>. Cells were pre-incubated with 3.5^ 4.0 jLiCi/ml [
3
H]-inositol in 10 % FCS CM with 
or without 10 ]iiM PMA, for 19 h. [^ H]-IPs accumulation induced by drugs was measured at 37°C for 1 h. 
a, buffer control; b, 10 nM PAF; c, 10 nM PAF and 1 |iM PMA; d, 1 ]nM PMA. Data are the means 土 
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Fig.3.37 
Comparision of binding of pH]-PAF (2 nM) to mixed，non-adhesive and adhesive Balb/c mice 
resident PEC. The peritoneal lavage (mixed) cells in CM were incubated at 37°C for 2-3 h and 
peritoneal macrophages (adhesive cells) were adhered to the bottom of culture dish. The non-adhesive 
cells in the CM were collected. The cells (0.5 x 10^ ) were incubated with 2 nM [
3
H]-PAF at room 
temperature for 1 h. a and b represent the binding in the absence and presence of 2 jLiM PAF, 
respectively, c, represents the specific binding which was calculated by subtracting b from a. Data are 
the means of duplicate determinations which varied less than 10 % from a typical experiment. Similar 




H]-IPs ACCUMULATION IN MURINE RESIDENT 
PMO 
[?H]-IPs accumulation in murine resident PM^> was stimulated by PAF in a 
dose-dependent manner (Fig. 3.38). A maximal response was obtained at 1 nM 
PAF. Higher concentrations of PAF, on the other hand, resulted in a lower pH]-
IPs formation. The EC50 of PAF was estimated to be 0.082 士 0.02 nM (means 士 
S.D., n = 3). 
Similar to the situation observed in murine TG-PMO, there was more than 
100 % increase of 1 nM PAF-induced pH]-IPs accumulation after prolonged 
pretreatment of the resident PM<E> of Balb/c mice with 10 弘M PMA. FurtKermore, 
there was no inhibition of the PAF response by 1 /xM PMA under these conditions 
(Fig. 3.39). 
3.4.3 BINDING OF 0.2 nM [
3
H]-PAF TO Balb/c MICE RESIDENT PEC 
Based on the effect of PAF on [^ H]-IPs formation and the subnanomolar 
EC50 thus obtained, further study of [^ H]-PAF binding to resident PEC was 
performed at a lower concentration [
3
H]-PAF (Fig. 3.40). Significant specific 
binding of [^ H]-PAF was observed when the cells were incubated with 0.2 nM 
pH]-PAF at 20°C for 60 min. The specific binding increased proportionally with 
cell number from 1.25 - 10 x 10
6
 cells, supporting the existence of specific PAF 
receptors on resident peritoneal macrophages from Balb/c mice. 
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Fig.3.38 
Effect of PAF on [^ H]-IPs accumulation in Balb/c mice resident PMO. [^ H]-IPs accumulation was 
induced by PAF at 37°C for 1 h. Data are the means of duplicate determinations which varied less than 
10 % from a typical experiment. Similar results were obtained in three separate experiments. 
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Fig.3.39 
Effect of prolonged PMA pretreatment on [^ H]-IPs accumulation induced by 1 nM PAF in Balb/c 
mice resident PMO. Cells were pre-incubated with 3.5^ 4.0 jiiCi/ml [
3
H]-inositol in 10 % FCS CM with 
or without 10 juM PMA for 19 h. [
3
H]-IPs accumulation induced by drugs was measured at 37°C for 1 h. 
fl, buffer control; b, 1 nM PAF . c，1 nM PAF and 1 |uM PMA. Data are the means of duplicate 
determinations which varied less than 10 % from a typical experiment. Similar results were obtained in 
three separate experiments. 
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Fig.3.40 
Effect of cell number on the binding of [^ H]-PAF to Balb/c mice resident PEC. Binding of 0.2 nM 
[^ H]-PAF to different cell numbers of resident PEC from Balb/c mice was measured at 20°C for 1 h. ( o ) 
and (• ) represent the binding of [^ H]-PAF in the absence and presence of 0.2 JLIM PAF, respectively. 
Data are the means of duplicate determinations which varied less than 5 %. 
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3.4.4 SUPEROXIDE ANION PRODUCTION INDUCED BY PAF AND PMA 
IN MURINE RESIDENT PM<I> 
PMA (1 fiM) induced significant O2" production in resident PM^  from 
Balb/c mice from 0.4 to 8.1 nmol/10^ cells/h. However, similar to the 
thioglycollate-elicited peritoneal macrophages obtained from the same species, no 
stimulation of O2" production was detectable with 0.1 to 100 nM PAF. 
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CHAPTER FOUR. DISCUSSIONS 
4.1 PAF RECEPTOR ON PERITONEAL MACROPHAGES 
Radioligand binding assays，when properly executed, can be used to 
characterize specific receptors on cell membranes. Besides providing basic 
information on the affinity (Kd) of the receptor towards different ligands and 
the number of binding sites available (Bmax)，they may also give insight on 
the possible existence of multiple receptor subtypes. Prpic et al. have reported 
the existence of two classes of specific PAF receptors on purified membrane 
derived from thioglycollate- and proteose peptone-elicited peritoneal 
macrophages of C57 mice with Kds of 2.4 nM and 0.1 nM, respectively [103]. 
4.1.1 [3H]-PAF BINDING TO PERITONEAL MACROPHAGES 
In the present study, [^ H]-PAF was used to characterize the PAF 
receptors on peritoneal macrophages from mice and guinea pigs. Binding of 
[3H]-PAF to intact macrophages was found to be both time- and temperature-
dependent and specific binding reached equilibrium within 1 h when the cells 
were incubated with 2 nM [
3
H]-PAF at 20°C. 
Specific binding of pH]-PAF was proportional to the cell number used 
and increased linearly in the region of 0.5 to 2.5 x 10^  cells. Similar to that 
reported for platelets and neutrophils [52,57,63], the specific binding of [^ H]-
PAF to macrophages was saturable and stereoselective, preferring the naturally 
occurring L-isomer over the D-isomer of PAF. 
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PAF antagonists of diverse chemical structures, including a ginkgolide, 
BN52021; a triazolodiazepine, BN50739 and several labdane diterpenes, LC-
5504, LC-5506, LC-5507, LC-5508 and LC-5509 were capable of inhibiting 
specific [3H]-PAF binding to thioglycollate elicited peritoneal macrophages. 
The rank order of potencies of these PAF antagonists in inhibiting specific 
[3H]-PAF binding to mouse and guinea pig peritoneal macrophages was quite 
similar: BN50739 » LC-5507 > LC-5508 >= LC-5509 > LC-5506 >= LC-
5504 >=BN52021 in mice and BN50739 » LC-5507 > LC-5509 > BN52021 
>=LC-5508 >= LC-5504 >= LC-5506 in guinea pigs. This pattern, however, 
differs significantly from that observed in rabbit platelets where: BN50739 » 
LC-5507 > BN52021 >= LC-5509 > LC-5506 >= LC-5504 >= LC-5508. " 
Moreover, all of these compounds, with the exception of BN50739, 
were 3-10 fold more active as inhibitors of [
3
H]-PAF binding to intact rabbit 
platelets than intact macrophages from mice and guinea pigs. WEB 2086， 
another specific PAF receptor antagonist, has been reported to be 10 fold less 
active in antagonizing the effects of PAF in guinea pig peritoneal macrophages 
than rabbit platelets and PMN [122]. Lambrecht et al. (1986) also reported 
that kadsurenone is 100 fold less potent on peritoneal macrophages than on 
PMN [69]. Moreover，Ono-6240 is 10 fold less active on PMN than on 
platelets in [^ H] -PAF binding [52]. It is possible that different subtypes of 
PAF receptors may exist on platelets and macrophages which have different 
affinities for these PAF antagonists. 
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In the present study, BN52021, BN50739, LC-5504, LC-5506 and LC-
5509 were found to be more potent in inhibiting [
3
H]-PAF binding to guinea 
pig than murine TG-PEC while LC-5507 and LC-5508 have similar potency 
against [%]-PAF binding to TG-PEC from both species. Hwang et al (1986) 
found that L-652，731，another PAF antagonist, is about 10 fold more potent in 
inhibiting [^ H]-PAF binding to rabbit than human platelet membranes [53]. 
These data suggest there may be a species difference at the binding site of the 
receptor of PAF. 
4.1.2 EXPRESSION OF PAF RECEPTOR ON Balb/c MICE 
PERITONEAL MACROPHAGES 
It has been proposed that PAF receptor expression on cell 
membrane is essential to the action of PAF [15]. Scatchard analysis reveals a 
Kd of 1.62 土 0.53 nM for specific binding of [3H]-PAF to Balb/c TG-
peritoneal macrophages, which is comparable to the EC50 of PAF in inducing 
[3H]-IPS accumulation in the same cells (0.91 土 0.31 nM). Under the same 
radioligand binding assay conditions, resident peritoneal macrophages of 
Balb/c mice displayed no specific binding of [^ H]-PAF. Either there is no 
PAF receptor expression on the resident peritoneal macrophages or there is too 
little PAF receptors to be detected. Since PAF can induce pH]-IPs 
accumulation in resident macrophages from Balb/c mice with an EC50 of 
0.082 土 0.02 nM. The existence of high affinity PAF receptors on Balb/c 
resident peritoneal macrophages was suspected. Moreover，[^ H]-IPs 
accumulation induced by PAF actually decreased at higher concentration (> 1 
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nM) suggesting that higher concentration of PAF may desensitize these 
receptors. Based on the results of [^ H]-IPs accumulation, receptor binding 
assay was performed at 0.2 nM [
3
H]-PAF (10 fold less than in TG-peritoneal 
macrophages) in order to maximize the chance of detecting the high affinity 
site. Indeed, specific binding 
of[
3
H]-PAF to resident PEC was observed under 
this condition, supporting the existence of a high affinity PAF receptor on 
resident peritoneal macrophages. However, in spite of the ability of PAF to 
stimulate [^ H]-IPs accumulation in resident peritoneal macrophages as well as 
TG-peritoneal macrophages of Balb/c mice, it was not able to stimulate the 
production of superoxide anion in these cells. This is quite different from the 
guinea pig TG-peritoneal macrophages, where PAF can stimulate both T^ H]-
IPs accumulation and superoxide production. 
PAF has also been reported to induce 6-oxo-PGFi generation from 
guinea pig resident peritoneal macrophages [122]，indicating that there are 
functional PAF receptors on these cells. 
4-2 SUPEROXIDE ANION PRODUCTION IN PERITONEAL 
MACROPHAGES 
PMA, a protein kinase C activator, can induce superoxide anion 
production in resident and thioglycollate-elicited peritoneal macrophages from 
mice and guinea pigs. Although the response of the thioglycollate-elicited 
macrophages was higher than the resident macrophages, it is clear that both 
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resident and stimulated macrophages possess the relevant enzymatic pathways 
to produce superoxide anion in response to PKC activation. 
On the other hand, PAF can induce superoxide production in peritoneal 
macrophages from guinea pigs but not those from Balb/c mice. PAF specific 
antagonists including BN50739 and LC-5507 can inhibit the PAF-induced 
production of superoxide anion in guinea pig macrophages supporting the 
notion that this action of PAF is a receptor-mediated response. 
The effects of supramaximal doses of PAF and PMA on superoxide 
production in guinea pig TG-PM巾 were additive. This may be taken as 
indication that the PAF-induced superoxide production in these cells occurs 
through a PKC-independent pathway. 
A23187，calcium ionophore, did not stimulate the production of 
superoxide anion in both murine and guinea pig peritoneal macrophages and it 
has no effect on the PAF-induced superoxide production in the guinea pig TG-
PMO. Therefore, it is unlikely that the PAF-induced superoxide production in 
macrophages occurs through a Ca
++
-dependent pathway. 
It has been reported that there are two distinctive pathways in human 
PMN cells and eosinophils as well as guinea pig PMN cells which can 
stimulate the respiratory burst response [60,61,93]. One is Ca
++
/PKC 
dependent, and other is Ca
++
/PLC/PKC independent [10]. Although the PAF-
induced superoxide production in normal bone marrow-derived macrophages 
[50]，guinea and human PMN cells [60,93] has been reported to be related to 
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PKC activation and that in guinea pig albumin-elicited PM<^  was inhibited by 
W_7，a calmodulin inhibitor [44], the PAF-induced superoxide production 
seems to be Ca
++
/PKC-independent in guinea pig TG-PMO based on the 
above data. Thus, the involvement of other signal transduction pathways in the 
mechanism of PAF-induced superoxide production in guinea pig TG-PM^> 
remains to be explored. 
4.3 PAF RECEPTOR AND POLYPHOSPHATIDYLINOSITOL 
SYSTEM IN PERITONEAL MACROPHAGES 
PAF has been reported to induce PIP2 hydrolysis in rabbit platelets 
[108]，normal bone marrow-derived macrophages [50] and murine peritoneal 
mcrophages [98，103，131]. In the present study, I have shown that PAF can 
also induce the accumulation of [^ H]-IPs and formation of [^ H]-IP3 in 
peritoneal macrophages from mice and guinea pigs presumably as a result of 
the hydrolysis of PIP2. 
In platelets [89]，PKC has been reported to exert a negative feedback 
control on the PIP2 turnover induced by PAF. For instance, the presence of 
PKC activators can inhibit the production of IPs induced by PAF. Conversely, 
when PKC activity is inhibited with staurosporine，PAF-induced IPs 
accumulation is enhanced. Similar result has been observed in the present 
study in murine and guinea pig TG-peritoneal macrophages. PMA inhibited 
the [3H]-IPS accumulation induced by 10 nM PAF with IC50 of 5.7 and 1.4 
nM in murine and guinea pig macrophages, respectively. 
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Prolonged (19 h) pretreatment of murine macrophages with 10 |LIM 
PMA to down-regulated PKC enhanced PAF (10 nM)-induced [
3
H]-IPs 
accumulation by 90-100 %. However, an enhancement of PAF-induced [^ H]-
IPs accumulation after PMA prolonged pretreatment cannot be observed in 
guinea pig macrophages. It has been reported that many cell types can express 
several PKC isozymes in different ratios [34,59] and these isozymes can be 
down-regulated by PMA at different rates [49]. Huang et al. (1989) reported 
that immunoblot analysis with PKC isozyme specific antibodies revealed a 
faster degradation of type p isoform of PKC induced by PMA than that of a 
isoform in rat basophilic leukemia RBL-2H3 cells [49]. Further experiments to 
measure PKC activity will be required to determine whether the differences in 
the PAF response to prolonged PMA pretreatment is related to the difference in 
PKC isozymes in murine and guinea pig peritoneal macrophages. 
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CHAPTER FIVE. CONCLUSIONS 
Prehispanolone, LC-5504 and its derivatives, LC-5506, LC-5507，LC-
5508 and LC-5509 are novel PAF receptor antagonists and they can inhibit 
pH]-PAF binding to rabbit platelets [72]. These compounds, as well as 
BN52021 and BN50739 can also inhibit [
3
H]-PAF binding to TG-PEC. The 
rank order of potencies of these PAF antagonists in inhibiting specific [^ H]-
PAF binding to Balb/c mice and guinea pigs peritoneal macrophages were 
similar: BN50739 » LC-5507 > LC-5508 >= LC-5509 > LC-5506 >= LC-
5504 >=BN52021 in mice and BN50739 » LC-5507 > LC-5509 > BN52021 
>=LC-5508 >= LC-5504 >= LC-5506 in guinea pigs. This pattern differs 
from that observed in rabbit platelets where: BN50739 » LC-5507 > 
BN52021 >二 LC-5509 > LC-5506 >= LC-5504 >= LC-5508. Moreover，all of 
these compounds, except BN50739，were 3-10 fold less active in inhibiting 
[
3
H]-PAF binding to TG-PEC from mice and guinea pigs than rabbit platelets. 
While LC-5507 and LC-5508 have similar potency against [
3
H]-PAF binding 
to TG-PEC of both Balb/c mice and guinea pigs, BN52021，BN50739，LC-
5504, LC-5506 and LC-5509 were more potent in inhibiting [3H]-PAF binding 
to guinea pig TG-PEC. The present result supports the possibility that 
different subtypes of PAF receptors may exist on platelets and macrophages 
and there may also be species differences in PAF receptors on macrophages. 
Scatchard analysis of specific [^ H]-PAF binding to TG-PMO from 
Balb/c mice revealed the presence of a single binding site for pH]-PAF with 
an apparent Kd of 1.62 土 0.53 nM which is similar to the EC50 of PAF in 
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inducing [^ H]-IPs accumulation (0.91 土 0.31 nM). This is in contrary to the 
findings of Prpic et al. who have reported the existence of two classes of PAF 
receptors on TG-PMO from C57 mice, with Kds of 2.4 and 0.1 nM [103]. 
This discrepancy may be the result of different species of mice used. Specific 
binding of [^ H]-PAF to resident PEC of Balb/c mice can only be obtained 
when receptor binding assay was performed at 0.2 nM but not at 2 nM [^ H]-
PAF. The EC50 of PAF in inducing [^ H]-IPs accumulation in Balb/c mice 
resident peritoneal macrophages was 0.1 nM, supporting the existence of PAF 
receptors with high affinity on these cells. 
Scatchard analysis also revealed the presence of a single binding site for 
[
3
H]-PAF to guinea pig TG-peritoneal macrophages with a Kd of 0.4 nM. 
PAF can induce superoxide anion production in guinea pig TG-
peritoneal macrophages but not in Balb/c mice. On the other hand, PMA can 
significantly increase superoxide production in murine and guinea pig resident 
or TG-peritoneal macrophages whereas A23187, cannot. PMA exhibited an 
additive effect on superoxide production induced by a supramaximal dose of 
PAF and A23187 did not enhance the production of superoxide induced by 
PAR Based on the above data, it is suggested that the PAF-induced 




On the other hand, PKC was found to exert a negative feedback on the 
PAF-induced PIP2 hydrolysis in peritoneal macrophage as reported previously 
in platelets and normal bone marrow-derived macrophages [50,89]. Moreover, 
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prolonged PMA (10 juM) pretreatment of macrophages enhanced the PAF-
induced [3H]-IPS accumulation in Balb/c mice but not in guinea pigs. It is 
suggested that PKC activity of the macrophages can be down-regulated by 
prolonged PMA pretreatment in mice but not in guinea pigs. 
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